

Vicki Lynn Ellingrod (Ringold)

Curriculum Vitae

Work Address:

University of Michigan
College of Pharmacy
428 Church Street
Ann Arbor, Michigan 48109-1065
Office: 734-764-7144
e-mail: vellingr@med.umich.edu

EDUCATION

- 1995-1996 American College of Clinical Pharmacy (ACCP), Psychopharmacology Fellowship. University of Iowa, College of Pharmacy, Iowa City, Iowa
- 1994-1996 Clinical Research Fellowship in Psychopharmacology. University of Iowa, College of Pharmacy, Iowa City, Iowa
Major Advisor: Paul J. Perry, Ph.D.
- 1992-1994 Doctor of Pharmacy. University of Minnesota, Minneapolis, MN,
- 1989-1992 Bachelor of Science, Pharmacy, University of Minnesota, Minneapolis, MN
- 1986-1989 Augsburg College, Minneapolis, MN

PROFESSIONAL EXPERIENCES

- July 2022-present Dean, College of Pharmacy, University of Michigan
- September 2020-June 2022 Senior Associate Dean, College of Pharmacy, University of Michigan
- April 2018-present Scientific Editor, *Journal of Clinical and Translational Science*
- September 2019-present Editor, Pharmacotherapy Handbook
- October 2017-present Lead, Education Workgroup, Precision Health Initiative, University of Michigan
- January 2017-present Editor, *Pharmacotherapy: A Pathophysiologic Approach*
- September 2016-Aug 2020 Associate Dean for Research and Graduate Education, College of Pharmacy, University of Michigan
- April 2016-present Associate Director for the Michigan Institute for Clinical Health Research (MICHR), University of Michigan

September 2015-2016	Deputy Editor, <i>Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition</i>
February 2015-present	Director of for the Michigan Institute for Clinical Health Research (MICHR) Education and Mentoring Group, University of Michigan
June 2014- present	Faculty Lead for the Michigan Institute for Clinical Health Research (MICHR) Mentored Clinical Scientist Career Development Award Program (MICHR K), University of Michigan
November 2013- June 2015	Associate Chair, University of Michigan, College of Pharmacy, Department of Clinical Social and Administrative Sciences
November 2013-present	Scientific Editor, <i>Pharmacotherapy</i>
December 2012 – present	John Gideon Searle Professor of Clinical and Translational Pharmacy, University of Michigan, College of Pharmacy, Department of Clinical Social and Administrative Sciences
September 2012-present	Professor (with tenure), University of Michigan, College of Pharmacy, Department of Clinical Sciences and College of Medicine, Department of Psychiatry, Ann Arbor, Michigan
July 2012	Faculty Member Educational Core, Michigan Institute for Clinical Research (MICHR)
July 2012	Member, Mental Health Initiative, Michigan Institute for Clinical Research (MICHR)
June 2010-June 2022	Savvy Psychopharmacology Department Editor, <i>Current Psychiatry</i>
January 2008-present	Member, Editorial Board, <i>Pharmacogenomics & Personalised Medicine</i>
January 2008-2012	Member Scientific Review/Research Committee, Michigan Institute for Clinical Research (MICHR)
August 2007-present	Director, Pharmacogenomics Laboratory, University of Michigan College of Pharmacy
July 2007-present	Member, University of Michigan Comprehensive Depression Center Steering Committee
January 2007-present	Member, National Alliance for Mentally Ill (NAMI) Scientific Research Council
October 2006present	Member, Michigan Metabolomics and Obesity Center (MMOC)
October 2006–present	Member, Michigan Diabetes Research and Training Center, University of Michigan, College of Medicine, Ann Arbor, Michigan
August 2006-present	Member, Editorial Board, <i>Pharmacotherapy</i>
July 2006–present	Active Faculty Member, Depression Center. University of Michigan, College of Medicine, Department of Psychiatry, Ann Arbor, Michigan

July 2006–2012	Associate Professor (with tenure), University of Michigan, College of Pharmacy, Department of Clinical Sciences and College of Medicine, Department of Psychiatry, Ann Arbor, Michigan
July 2004–2005	Chair, Clinical Pharmaceutical Sciences Ph.D. program. University of Iowa, College of Pharmacy, Iowa City, Iowa. Clinical and Administrative Pharmacy Division
July 2004–2006	Associate Professor (with tenure), Clinical and Administrative Pharmacy Division, University of Iowa, College of Pharmacy, Iowa City, Iowa
Sept 1999-2006	Adjunct Clinical Instructor University of Iowa, College of Nursing, Iowa City, Iowa
1999–2004	Assistant Professor, University of Iowa, Clinical and Administrative Pharmacy Division, College of Pharmacy, Iowa City, Iowa
1998-2006	Director, Pharmacogenetics Laboratory, Clinical and Administrative Pharmacy Division, University of Iowa, College of Pharmacy, Iowa City, Iowa
1996-1999	Associate, Clinical and Administrative Pharmacy Division, University of Iowa, College of Pharmacy, Iowa City, Iowa
1992-1994	Clinical-Staff pharmacist, part-time to full-time, Fairview Riverside Medical Center Pharmacy, Minneapolis, MN
1988-1992	Pharmacy intern/student, Fairview Riverside Medical Center Pharmacy, Minneapolis, MN
1984-1989	Store clerk/technician, Valley View Drug Store, Edina, MN

BOARD CERTIFICATION

November 2006	Psychiatric Pharmacy
November 1997	Psychiatric Pharmacy

RESEARCH PROJECTS

Pending

UL1 TR000433 (Lumeng)	3/1/22 – 2/28/27	4.20 calendar
NIH	\$22,273	
Clinical and Translational Science Award		
The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.		

Current Projects (Funded)

U01 (Ellingrod) NIH	2/1/17-3/31/21 \$669,837	0.1 calendar
Development, Implementation and Assessment Of Novel Training in Domain-based Competencies (DIAMOND) The objective is to develop an online educational portal (DIAMOND portal) for competency-based educational offerings and assessments and to demonstrate integration of this curriculum into CTSA clinical trial education programs at DIAMOND hubs and partner sites in ways that promote the more effective, efficient, and safe execution of clinical trials; allowing for dissemination to a broader audience.		
U54 (Ellingrod) NIH	6/1/17-2/28/22 \$554,700	1.8 calendar
Michigan Institute for Clinical and Health Research (MICHR) - TL1 Award The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.		
U54 (Ellingrod) NIH	6/1/17-2/28/22 \$1,283,758	1.2 calendar
Michigan Institute for Clinical and Health Research (MICHR) - KL2 Award The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.		
U54 (Mashour) NIH	6/1/17-2/28/22 \$89,950	4.8 calendar
Michigan Institute for Clinical and Health Research (MICHR) - U-award The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.		

Previous Support

National Institute of Mental Health

05/01/08 – 6/30/19

Role: Role: Principal Investigator

25% effort, \$2,500,000 total costs

Antipsychotic and Folate Pharmacogenetics

- The major goal of this study is to examine folate pharmacogenomics in relation to metabolic syndrome, insulin resistance, and endothelial dysfunction from atypical antipsychotic use in schizophrenia and to determine the utility of folate supplementation in attenuation of these complications.

National Center for the Advancement of Translational Science (Mashour)

02/01/2015-05/31/17

Role: Education and Mentoring Faculty Lead

10% effort

Clinical and Translational Science Award

- The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.

National Institute of Mental Health
06/01/14-05/31/2015
Antipsychotic and Folate Pharmacogenetics” (R01 MH082784) Metabolomics Supplement
Role: Principal Investigator
2.5% Effort, \$155,500 total costs

- The purpose of this supplement is to generate metabolomics data that can be used to identify correlational relationships between metabolic profiles and clinical phenotypes of schizophrenia patients treated with AAPs.

National Institute of Mental Health Supplement
06/01/14-05/31/2015
Antipsychotic and Folate Pharmacogenetics” (R01 MH082784) Gender Supplement
Role: Principal Investigator
1.2% Effort, \$100,000 total costs

- The purpose of this study is to identify epigenome profile differences in race, age and folate status matched males and female subjects stratified by a metabolic syndrome diagnosis and determine gene-specific methylation differences associated with gender and metabolic syndrome in schizophrenia subjects.

National Institute of Mental Health R01MH090072 (Calarge)
08/01/10-06/30/15
Investigating the Effects of SSRIs on Bone Health in Adolescents
Role: Co-Investigator
5% Effort and salary support, \$124,086 (UM total costs)

- This investigation examines the pharmacogenomics of the serotonin system in relation to bone density effects of selective serotonin reuptake inhibitor use in adolescents

FDA HHSF223201310164C (Sun)
9/27/13-11/15/15 *Investigation of Release Profiles of Bupropion and Pharmacogenomics of Metabolism Enzymes for Bioequivalence of Generic Bupropion Products in Healthy Volunteers*
Role: Co-Investigator
10% Effort and Salary Support, \$185,794

- The objectives of this project are to understand whether and how the release pattern of bupropion HCl products and the genotype of metabolic enzyme affect the bioequivalence conclusions across different dose strengths within one product line due to the saturation of intestinal metabolism.

No number Sunovion (Touchette)
7/1/13-6/30/14
Beliefs And Attitudes Towards Antipsychotic Use In Patients With Schizophrenia And Bipolar Disorder
Role: Co-investigator
10% Effort and Salary Support, \$21,306 (UM total costs)

- The goal of this study is to describe how psychiatrist and pharmacist beliefs and perceptions regarding the effectiveness, safety, and cost affect the initial choice of atypical antipsychotics and actual use of these agents in the treatment of schizophrenia and bipolar disorder.

National Institute of Mental Health R01 MH082784 (Ellingrod)

05/01/08-01/31/13

Folate Pharmacogenomics and Risk of Atypical Antipsychotic Metabolic Side Effects

Role: Principal Investigator

25% Effort and salary support, \$1,250,000 (direct costs)/\$ 1,859,353 (total costs)

- The goal of this study is to examine folate pharmacogenomics in relation to metabolic syndrome, insulin resistance, and endothelial dysfunction from atypical antipsychotic use in schizophrenia and to determine the utility of folate supplementation in attenuation of these complications.

NIH/NCRR 1 UL1 RR024986 (Clauw/Pienta)

09/17/07-05/31/12

Clinical and Translational Science Award

Role: Member of Scientific Review Committee

2007-2010 5% Effort and salary support, 2010-present 2.5% Effort and salary support

- The goal is to review protocols and consult on investigations that use the General Clinical Research Center.

Michigan Institute for Clinical and Health Research (Bleske)

06/01/09–05/31/11

Role of Vitamin D in Heart Failure (Hemodynamics)

Role: Investigator

No salary support, \$5,000 (total costs)

- The purpose of this investigation is to examine the relationship between genetic variation in the vitamin D receptor and heart failure treatments

National Alliance for Schizophrenia and Depression (Ellingrod)

09/01/07–08/31/10

Folate pharmacogenomics and metabolic complications from atypical antipsychotic use in bipolar disorder

Role: Principal Investigator

10% Effort, no salary support, \$100,000 (total costs with 8% indirect rate)

- The primary goal of this study is to use explore the relationship between folate metabolism, and antipsychotic associated cardiovascular complications in a bipolar disorder population.

NIMH 5R21MH080968-02 (Calarge)

08/01/08-07/31/10

Long-term Safety and Genetic Risk Factors of Risperidone Treatment in Youth

Role: Co-Investigator

7.5% Effort and salary support, \$89,000 (total UM costs)

- The goal of this study is to follow-up subejcts who were part of Dr. Calarge's NARSAD project to determine longer term metabolic complications from antipsychtoic use and pharmacogenomic risk

Michigan Institute for Clinical and Health Research (Stringer)

09/01/07–08/31/08

Tissue Plasminogen Activator Polymorphisms in ARDS

Role: Investigator

No salary support, \$21,500 (total costs)

- The purpose of this study was to examine the role of genetic variability within the TPA gene and acute respiratory distress syndrome.

Nellie Ball Foundation (Fiedorowicz)

02/01/07–01/31/09

Cardiovascular Complications of Olanzapine in Affective Disorders

Role: Consultant

No salary support, \$100,000 (total costs)

- The goal of this pilot project is to better characterize the metabolic complications seen from olanzapine use in patients with bipolar depression.

University of Michigan Upjohn/Vahlteich Foundation (Ellingrod)

01/01/07–06/30/08

Genetic Predictors of Antipsychotic Associated Metabolic Syndrome

Role: Principal Investigator

No salary support, 40,000 (total costs)

- The goal of this pilot grant is to gather additional pilot data on the relationship of diet and nutrition to the development of metabolic syndrome with atypical antipsychotic use in schizophrenia.

National Alliance for Research in Schizophrenia and Depression (NARSAD) (Calarge)

07/01/05–06/30/07

The prevalence of long-term risperidone-induced hyperprolactinemia and its effect on sex hormones and BMD

Role: Investigator

No salary support, \$60,000 (total costs)

- The purpose of this study was to examine genetic variability within dopamine neurotransmitters and the occurrence of hyperprolactinemia in children receiving risperidone.

National Institute of Mental Health K08 MH64158 (Ellingrod)

07/01/01–07/31/06

Genetics of Antipsychotic Metabolism

Role: Principal Investigator

75-100% Effort and salary support, \$525,000 (total costs)

- The purpose of this study was to examine the pharmacogenetics of antipsychotic metabolism and weight gain

University of Iowa, College of Pharmacy, STIR award (Ellingrod)

2004-2006

Effect of DHEA Administration on the Metabolic Consequences of Atypical Antipsychotic Use in Schizophrenia

Role: Principal Investigator

10% Effort, no salary support, \$10,000 (total costs)

- The purpose of this proposal was to determine the effect of DHEA administration of the metabolic effects of atypical antipsychotic medications in schizophrenia.

University of Iowa, General Clinical Research Center (Fleckenstein)

2004-2006

An open-label sequential study to evaluate the effect of genetic polymorphisms and orange juice on ivermectin pharmacokinetics in health volunteers

Role: Investigator

5% Effort, no salary support, \$12,760 (total costs)

- This study examined genetic variability within drug transporters and the pharmacokinetics of ivermectin in health volunteers.

National Institute of Mental Health (Schultz)

2003-2005

Double Blind Placebo Controlled Trial of Ginkgo Biloba Augmentation of Donepezil, Effects on Clinical Outcome and Cerebral Blood Flow

Role: Investigator

5% Effort, no salary support, \$551,250 (total costs)

- This study examined the effect of ginkgo biloba augmentation of donepezil on cerebral blood flow and clinical outcomes.

University of Iowa GCRC Pilot Program (Ellingrod)

2003-2005

Pharmacogenomics of SSRI Induced Sexual Dysfunction.

Role: Principal Investigator

10% Effort, no salary support, \$10,000 (total costs)

- The objective of this study was to examine the pharmacogenomics of sexual dysfunction associated with antidepressant treatment

Eli Lilly and Company (Ellingrod)

2003-2004

Reanalysis of Olanzapine dataset for -759C/T 5HT2CR polymorphism.

Role: Principal Investigator

5% Effort, no salary support, \$10,000 (total costs)

- This study reexamined a dataset of olanzapine treatment subjects to determine the role of 5HT2CR variants on weight gain.

Eli Lilly and Company (Perry)

2000-2002

5HT2A and 5HT2C Receptor Polymorphism Responsible for Predicting Clinical Response to the Antipsychotic Olanzapine

Role: Co-Principal Investigator

5% Effort, no salary support, \$75,000 (total costs)

- This was a clinical trial examining the role of serotonin variants on predicting clinical response to olanzapine.

American College of Clinical Pharmacy (Ellingrod)

1999-2002

Comparison of Atypical Antipsychotics In Elderly Dementia Patients With Psychosis: Effects on Outcome, Symptom Response, Cognition, and Adverse Medication Effects

Role: Principal Investigator

10% Effort, no salary support, \$10,000 (total costs)

- This study examined the cognitive effects of atypical antipsychotic use in elderly subjects.

American College of Clinical Pharmacy (Perry/Ellingrod)

1995-1996

Genetic Markers and Drug Metabolism in Children with Tricyclic Induced Arrhythmias

Role: Principal Investigator, Fellowship

75% Effort, no salary support, \$10,000 (total costs)

- This study was part of the ACCP Fellowship program and supported a study examining the relationship between CYP2D6 variability and EKG changes seen in children on tricyclic antidepressants

PUBLICATIONS

* indicates trainee under Dr. Ellingrod's supervision

Original Research

- 1) Deumic Shultz E, Mills JA, **Ellingrod VL**, Bishop JR, Calarge CA. Sexual Functioning in Adolescents With Major Depressive Disorder: A Prospective Study. *J Clin Psychiatry*. 2021 Oct 5;82(6):21m13892. doi: 10.4088/JCP.21m13892. PMID: 34610228.
- 2) *Ianni PA, Samuels EM, Eakin BL, Perorazio TE, **Ellingrod VL**. Assessments of Research Competencies for Clinical Investigators: A Systematic Review. *Eval Health Prof*. 2021 Sep;44(3):268-278. doi: 10.1177/0163278719896392. Epub 2019 Dec 23. PMID: 31867997; PMCID: PMC8274959.
- 3) Irwin MN, **Ellingrod VL**, Smith MA. Pharmacogenetics of methadone for pain management in palliative care. *J Pain Symptom Manage*. 2021 Aug 27:S0885-3924(21)00519-4. doi: 10.1016/j.jpainsymman.2021.08.007. Epub ahead of print. PMID: 34461232.
- 4) *Kumar P, Kraal AZ, Prawdzik AM, Ringold AE, **Ellingrod V**. Dietary Glutamic Acid, Obesity, and Depressive Symptoms in Patients With Schizophrenia. *Front Psychiatry*. 2021 Jan 21;11:620097. doi: 10.3389/fpsy.2020.620097. PMID: 33551881; PMCID: PMC7859478.
- 5) Lim M, Nascimento TD, Kim DJ, **Ellingrod VL**, DaSilva AF. Aberrant Brain Signal Variability and COMT Genotype in Chronic TMD Patients. *J Dent Res*. 2021 Jul;100(7):714-722. doi: 10.1177/0022034521994089. Epub 2021 Feb 23. PMID: 33622085; PMCID: PMC8221705.
- 6) Morris MR, Hoeflich CC, Nutley S, **Ellingrod VL**, Riba MB, Striley CW. Use of psychiatric medication by college students: A decade of data. *Pharmacotherapy*. 2021 Apr;41(4):350-358. doi: 10.1002/phar.2513. Epub 2021 Mar 5. PMID: 33583071.
- 7) *Manzor Mitrzyk B, Plegue MA, Kadri R, Danak SU, Hubbard JD, Kaip EA, Roberson DN, Roy S, Guetterman TC, **Ellingrod VL**, Farris KB, Ruffin IV MT, Klinkman MS, Buis LR. Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions. *Per Med*. 2021 May;18(3):233-240. doi: 10.2217/pme-2020-0084. Epub 2021 Mar 17. PMID: 33728996.
- 8) *Manzor Mitrzyk B, Plegue MA, Kadri R, Danak SU, Hubbard JD, Kaip EA, Roberson DN, **Ellingrod VL**, Farris KB, Ruffin MT 4th, Klinkman MS, Buis LR. Pharmacogenomic testing for mental health (Part I): documenting early adopter

perceptions of use for eight scenarios. *Per Med.* 2021 May;18(3):223-232. doi: 10.2217/pme-2020-0083. Epub 2021 Mar 17. PMID: 33728966.

- 9) Pasternak AL, Ward KM, Ateya MB, Choe HM, Thompson AN, Clark JS, **Ellingrod V**. Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center. *J Pers Med.* 2020 Oct 3;10(4):154. doi: 10.3390/jpm10040154. PMID: 33023029; PMCID: PMC7711716.
- 10) Ianni PA, Samuels EM, Eakin BL, Perorazio TE, **Ellingrod VL**. Assessments of Research Competencies for Clinical Investigators: A Systematic Review. *Eval Health Prof.* 2019 Dec 23:163278719896392. doi: 10.1177/0163278719896392. Epub ahead of print. PMID: 31867997.
- 11) Taylor SF, Grove TB, **Ellingrod VL**, Tso IF. The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis. *Schizophr Bull.* 2019 Oct 24;45(6):1170-1183. doi: 10.1093/schbul/sbz046. PMID: 31150555; PMCID: PMC6811817.
- 12) Nascimento TD, Yang N, Salman D, Jassar H, Kaciroti N, Bellile E, Danciu T, Koeppe R, Stohler C, Zubieta JK, **Ellingrod V**, DaSilva AF. μ -Opioid Activity in Chronic TMD Pain Is Associated with COMT Polymorphism. *J Dent Res.* 2019 Nov;98(12):1324-1331. doi: 10.1177/0022034519871938. Epub 2019 Sep 6. PMID: 31490699; PMCID: PMC6806132.
- 13) *Manzor Mitrzyk B, Kadri R, Farris KB, **Ellingrod VL**, Klinkman MS, Ruffin Iv MT, Plegue MA, Buis LR. Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study. *JMIR Res Protoc.* 2019 Aug 19;8(8):e13848. doi:10.2196/13848. PubMed PMID: 31429417.
- 14) *Kraal AZ, *Moll AC, *Arvanitis NR, *Ward KM, *Dougherty RJ, *Grove TB, *Burghardt KJ, **Ellingrod VL**. Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)- 786C carriers in schizophrenia-spectrum disorders. *J Psychiatr Res.* 2019 Oct;117:142-147. doi: 10.1016/j.jpsychires.2019.07.006. Epub 2019 Jul 26. PubMed PMID: 31421598.
- 15) Touchette DR, Gor D, Sharma D, Chennault RR, Ng-Mak DS, Rajagopalan K, **Ellingrod V**. Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders. *J Pharm Pract.* 2019 Jun 25:897190019854566. doi: 10.1177/0897190019854566. [Epub ahead of print] PubMed PMID: 31238761.
- 16) Hornung CA, Ianni PA, Jones CT, Samuels EM, **Ellingrod VL**; DIAMOND Investigators. Indices of Clinical Research Coordinators' Competence. *J Clin Transl Sci.* 2019 Jun;3(2-3):75-81. doi: 10.1017/cts.2019.381. Epub 2019 Jul 24. PMID: 31552144; PMCID: PMC6759060.
- 17) Byks-Jazayeri C, Samuels E, Anderson EW, **Ellingrod VL**. Implementing and measuring the impact of a clinical and translational research mentor recognition program. *J Clin Transl Sci.* 2018 Oct;2(5):312-320. doi: 10.1017/cts.2018.329. PubMed PMID: 30828473; PubMed Central PMCID: PMC6390404.
- 18) *Kraal AZ, *Arvanitis NR, *Jaeger AP, **Ellingrod VL**. Could Dietary Glutamate Play a Role in Psychiatric Distress? *Neuropsychobiology.* 2019 Jan 30:1-7. doi: 10.1159/000496294. [Epub ahead of print] Review. PubMed PMID: 30699435; PubMed Central PMCID: PMC6667320.
- 19) *Flowers SA, Baxter NT, Ward KM, Kraal AZ, McInnis MG, Schmidt TM, **Ellingrod VL**. Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with

- Bipolar Disorder or Schizophrenia. *Pharmacotherapy*. 2019 Jan 8. doi: 10.1002/phar.2214. [Epub ahead of print] PubMed PMID: 30620405.
- 20) *Kim E, Ndege PK, Jackson E, Clauw DJ, Ellingrod VL. Patient perspectives on medication self-management in rural Kenya: a cross-sectional survey. *Int J Qual Health Care*. 2019 Jun 1;31(5):353-358. doi: 10.1093/intqhc/mzy187. PMID: 30256956.
- 21) Burghardt KJ, Goodrich JM, Lines BN, **Ellingrod VL**. The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia. *Int J Genomics*. 2018 Apr 3;2018:8076397. doi: 10.1155/2018/8076397. eCollection 2018. PubMed PMID: 29850476; PubMed Central PMCID: PMC5903198.
- 22) Grove TB, Yao B, Mueller SA, McLaughlin M, **Ellingrod VL**, McInnis MG, Taylor SF, Deldin PJ, Tso IF. A Bayesian model comparison approach to test the specificity of visual integration impairment in schizophrenia or psychosis. *Psychiatry Res*. 2018 Jul;265:271-278. doi: 10.1016/j.psychres.2018.04.061. Epub 2018 May 7. PubMed PMID: 29768190.
- 23) *Ward KM, Yeoman L, McHugh C, Kraal AZ, Flowers SA, Rothberg AE, Karnovsky A, Das AK, **Ellingrod VL**, Stringer KA. Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. *Pharmacotherapy*. 2018 Jun;38(6):638-650. doi: 10.1002/phar.2119. PubMed PMID: 29722909; PubMed Central PMCID: PMC6014920.
- 24) Yao B, Mueller SA, Grove TB, McLaughlin M, Thakkar K, **Ellingrod V**, McInnis MG, Taylor SF, Deldin PJ, Tso IF. Eye gaze perception in bipolar disorder: Self-referential bias but intact perceptual sensitivity. *Bipolar Disord*. 2018 Feb;20(1):60-69. doi: 10.1111/bdi.12564. Epub 2017 Nov 23. PubMed PMID: 29168603; PubMed Central PMCID: PMC5807101.
- 25) Pasternak AL, Ward KM, Luzum JA, **Ellingrod VL**, Hertz DL. Germline genetic variants with implications for disease risk and therapeutic outcomes. *Physiol Genomics*. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Review. PubMed PMID: 28887371; PubMed Central PMCID: PMC5668651.
- 26) Bishop JR, **Ellingrod VL**. Precision Pharmacotherapy Enables Precision Medicine. *Pharmacotherapy*. 2017 Sep;37(9):985-987. doi: 10.1002/phar.1998. Epub 2017 Aug 23. PubMed PMID: 28836287.
- 27) Hertz DL, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, **Ellingrod VL**. Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. *Pharmacogenomics*. 2017 Jul 26. doi: 10.2217/pgs-2017-0107. [Epub ahead of print] PubMed PMID: 28745551.
- 28) *Kraal AZ, Ward KM, **Ellingrod VL**. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. *Psychopharmacol Bull*. 2017 May 15;47(2):8-21. PubMed PMID: 28626268; PubMed Central PMCID: PMC5472174.
- 29) Connarn JN, Flowers S, Kelly M, Luo R, Ward KM, Harrington G, Moncion I, Kamali M, McInnis M, Feng MR, **Ellingrod V**, Babiskin A, Zhang X, Sun D. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. *AAPS J*. 2017 Sep;19(5):1513-1522. doi: 10.1208/s12248-017-0102-8. Epub 2017 Jul 6. PubMed PMID: 28685396.

- 30) Eddington Chair ND, Aubé J, Das SK, **Ellingrod VL**, Hansen R, Madhavan SS, Monks TJ, Morris ME, Lakoski Staff Liaison JM. Report of the 2014-2016 AACP Research and Graduate Affairs Committee. *Am J Pharm Educ.* 2016 Nov 25;80(9):S21. doi: 10.5688/ajpe809S21. PubMed PMID: 28090116; PubMed Central PMCID: PMC5222741.
- 31) *Flowers SA, Evans SJ, Ward KM, McInnis MG, **Ellingrod VL**. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. *Pharmacotherapy.* 2017 Mar;37(3):261-267. doi: 10.1002/phar.1890. Epub 2017 Feb 20. PubMed PMID: 28035686.
- 32) Hirasawa-Fujita M, Bly MJ, **Ellingrod VL**, Dalack GW, Domino EF. Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. *Clin Schizophr Relat Psychoses.* Spring 2017;11(1):39-48. doi: 10.3371/1935-1232-11.1.39. PubMed PMID: 28548579; PubMed Central PMCID: PMC4366347.
- 33) Hicks JK, Sangkuhl K, Swen JJ, **Ellingrod VL**, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther.* 2016 Dec 20. doi: 10.1002/cpt.597. [Epub ahead of print] PubMed PMID: 27997040; PubMed Central PMCID: PMC5478479.
- 34) Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, Young VB, **Ellingrod VL**, McInnis MG. The gut microbiome composition associates with bipolar disorder and illness severity. *J Psychiatr Res.* 2017 Apr;87:23-29. doi: 10.1016/j.jpsychires.2016.12.007. Epub 2016 Dec 10. PubMed PMID: 27988330; PubMed Central PMCID: PMC5336480.
- 35) *Ward KM, Kraal AZ, Flowers SA, **Ellingrod VL**. Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. *Pharmacotherapy.* 2017 Sep;37(9):1122-1130. doi: 10.1002/phar.1968. Epub 2017 Aug 2. PubMed PMID: 28605058; PubMed Central PMCID: PMC5600660.
- 36) *Grove TB, Burghardt KJ, Kraal AZ, Dougherty RJ, Taylor SF, **Ellingrod VL**. Oxytocin Receptor (OXTR) Methylation and Cognition in Psychotic Disorders. *MolNeuropsychiatry.* 2016 Oct;2(3):151-160. PubMed PMID: 27867940.
- 37) Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, **Ellingrod VL**, Kamali M, McInnis M, Sun D. Identification of Non-Reported Bupropion Metabolites in Human Plasma. *Biopharm Drug Dispos.* 2016 Oct 10. doi:10.1002/bdd.2046. [Epub ahead of print] PubMed PMID: 27723114.
- 38) *Burghardt KJ, Goodrich JM, Dolinoy DC, **Ellingrod VL**. Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. *Bipolar Disord.* 2016 Aug;18(5):423-32. doi: 10.1111/bdi.12422. PubMed PMID:27542345.
- 39) *Grove TB, Tso IF, Chun J, Mueller SA, Taylor SF, **Ellingrod VL**, McInnis MG, Deldin PJ. Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis. *Psychiatry Res.* 2016 Sep 30;243:198-206. doi: 10.1016/j.psychres.2016.06.031. PubMed PMID: 27416540; PubMed Central PMCID: PMC5014676.
- 40) *Flowers SA, Ryan KA, Lai Z, McInnis MG, **Ellingrod VL**. Interaction between COMTrs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. *BMC Psychol.* 2016 Apr

2;4:14. doi: 10.1186/s40359-016-0118-3. PubMed PMID: 27039372; PubMed CentralPMCID: PMC4818866.

- 41) *Burghardt KJ, Evans SJ, Wiese KM, **Ellingrod VL**. An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder. *Clin Transl Sci*. 2015 Oct;8(5):432-40. doi: 10.1111/cts.12324. Epub 2015 Aug 27. PubMed PMID: 26314700; PubMed Central PMCID: PMC4626284.
- 42) Fiedorowicz JG, **Ellingrod VL**, Kaplan MJ, Sen S. The development of depressive symptoms during medical internship stress predicts worsening vascular function. *J Psychosom Res*. 2015 Sep;79(3):243-5. doi: 10.1016/j.jpsychores.2015.06.004. Epub 2015 Jun 18. PubMed PMID: 26115588; PubMed Central PMCID: PMC4522220.
- 43) *Burghardt KJ, Goodrich JM, Dolinoy DC, **Ellingrod VL**. DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. *Epigenomics*.2015;7(3):343-52. doi: 10.2217/epi.15.5. PubMed PMID: 26077424; PubMed Central PMCID: PMC4501018.
- 44) *Grove T, Taylor S, Dalack G, **Ellingrod V**. Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. *Schizophr Res*. 2015 May;164(1-3):115-21. doi: 10.1016/j.schres.2015.02.006. Epub 2015 Feb 23. PubMed PMID: 25728832; PubMed Central PMCID: PMC4409513.
- 45) Hirasawa-Fujita M, Bly MJ, **Ellingrod VL**, Dalack GW, Domino EF. Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. *Clin Schizophr Relat Psychoses*. 2014 Jun 20:1-27. [Epub ahead of print]PubMed PMID: 24951719.
- 46) O'Malley M, King AN, Conte M, **Ellingrod VL**, Ramnath N. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. *J Thorac Oncol*. 2014 Jul;9(7):917-26. doi: 10.1097/JTO.0000000000000191. PubMed PMID: 24926542.
- 47) Del Castillo N, Zimmerman M B, Tyler B, **Ellingrod VL**, Calarge C. 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. *Clin Pharmacol Biopharm*. 2013 Jun29;2(2):110. PubMed PMID: 24772381; PubMed Central PMCID: PMC3997261.
- 48) Bleske BE, Remington TL, Wells TD, Dorsch MP, Guthrie SK, Stumpf JL, Alaniz MC, **Ellingrod VL**, Tingen JM. Team-based learning to improve learning outcomes in a therapeutics course sequence. *Am J Pharm Educ*. 2014 Feb 12;78(1):13. doi: 10.5688/ajpe78113. PubMed PMID: 24558281; PubMed Central PMCID: PMC3930237.
- 49) Dorsch MP, Nemerovski CW, **Ellingrod VL**, Cowger JA, Dyke DB, Koelling TM, Wu AH, Aaronson KD, Simpson RU, Bleske BE. Vitamin D Receptor Genetics on Extracellular Matrix Biomarkers and Hemodynamics in Systolic Heart Failure. *J Cardiovasc Pharmacol Ther*. 2014 Feb 4. [Epub ahead of print] PubMed PMID:24500905.
- 50) *Burghardt KJ, Gardner KN, Johnson JW, **Ellingrod VL**. Fatty Acid desaturase gene polymorphisms and metabolic measures in schizophrenia and bipolar patients taking antipsychotics. *Cardiovasc Psychiatry Neurol*. 2013;2013:596945. doi:10.1155/2013/596945. Epub 2013 Dec 21. PubMed PMID: 24455201; PMCID: PMC3880735.

- 51) *Burghardt K, Grove T, **Ellingrod V**. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. *J Psychopharmacol*. 2013 Dec 17. [Epub ahead of print] PubMed PMID: 24346810.
- 52) *Bly MJ, Taylor SF, Dalack G, Pop-Busui R, Burghardt KJ, Evans SJ, McInnis MI, Grove TB, Brook RD, Zöllner SK, **Ellingrod VL**. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. *Bipolar Disord*. 2013 Dec 13. doi:10.1111/bdi.12160. [Epub ahead of print] PubMed PMID: 24330321.
- 53) *Vassas TJ, Burghardt KJ, **Ellingrod VL**. Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. *Pharmacogenomics*. 2014 Jan;15(1):61-7. doi: 10.2217/pgs.13.157. PubMed PMID: 24329191.
- 54) Parker RB, **Ellingrod V**, DiPiro JT, Bauman JL, Blouin RA, Welage LS. Preparing clinical pharmacy scientists for careers in clinical/translational research: can we meet the challenge?: ACCP Research Affairs Committee Commentary. *Pharmacotherapy*. 2013 Dec;33(12):e337-46. doi: 10.1002/phar.1348. Epub 2013 Sep 30. PubMed PMID: 24114730.
- 55) Prossin AR, Zalcmán SS, Evans SJ, McInnis MG, **Ellingrod VL**. A pilot study investigating tumor necrosis factor- α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. *Ther Drug Monit*. 2013 Apr;35(2):194-202. doi: 10.1097/FTD.0b013e31827e18d2. PubMed PMID: 23503445; PMCID: PMC3623939.
- 56) Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, **Ellingrod VL**, Skaar TC, Müller DJ, Gaedigk A, Stingl JC; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. *Clin Pharmacol Ther*. 2013 May;93(5):402-8. doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16. Review. PubMed PMID: 23486447; PubMed Central PMCID: PMC3689226.
- 57) *Bly MJ, Bishop JR, Thomas KL, **Ellingrod VL**. P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects. *J Sex Marital Ther*. 2013;39(3):280-8. doi:10.1080/0092623X.2011.615896. Epub 2013 Jan 28. PubMed PMID: 23356581; PMCID: PMC3807815.
- 58) Yuan ST, **Ellingrod VL**, Schipper M, Stringer KA, Cai X, Hayman JA, Yu J, Lawrence TS, Kong FM. Genetic variations in TGF β 1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer. *J Thorac Oncol*. 2013 Feb;8(2):208-13. doi: 10.1097/JTO.0b013e318274592e. PubMed PMID: 23334061; PubMed Central PMCID: PMC3646090.
- 59) Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, **Ellingrod VL**, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. *Cancer Chemother Pharmacol*. 2013 May;71(5):1173-82. doi:. PubMed PMID: 23435876; PMC3637851.
- 60) Evans SJ, Kamali M, Prossin AR, Harrington GJ, **Ellingrod VL**, McInnis MG, Burant CF. Association of plasma omega-3 and omega-6 lipids with burden of disease measures in bipolar subjects. *J Psychiatr Res*. 2012 Aug 9. [Epub ahead of print] PubMed PMID: 22884424.

- 61) Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, **Ellingrod VL**, Haynes WG. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. *Curr Psychiatry Rev.* 2012 Feb 1;8(1):25-36. PubMed PMID: 22712004; PubMed Central PMCID: PMC3375952.
- 62) *Burghardt KJ, Pilsner JR, Bly MJ, **Ellingrod VL**. DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. *Epigenomics.* 2012 Jun;4(3):261-8. PubMed PMID: 22690662; PubMed Central PMCID: PMC3392683.
- 63) Bishop JR, Chae SS, Patel S, Moline J, **Ellingrod VL**. Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. *Psychiatry Res.* 2012 Apr 23. [Epub ahead of print] PubMed PMID: 22534499.
- 64) Lott SA, Burghardt PR, Burghardt KJ, Bly MJ, Grove TB, **Ellingrod VL**. The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. *Pharmacogenomics J.* 2012 Mar 6. doi: 10.1038/tpj.2012.6. [Epub ahead of print] PubMed PMID: 22391769.
- 65) Evans SJ, Prossin AR, Harrington GJ, Kamali M, **Ellingrod VL**, Burant CF, McInnis MG. Fats and Factors: Lipid Profiles. Associate with Personality Factors and Suicidal History in Bipolar Subjects. *PLoS One.* 2012;7(1):e29297. Epub 2012 Jan 13. PubMed PMID: 22253709; PubMed Central PMCID: PMC3258247.
- 66) **Ellingrod VL**, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zöllner SK, Pop-Busui R. Risk Factors Associated with Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With Antipsychotics: The Role of Folate Pharmacogenetics. *J Clin Psychopharmacol.* 2012 Apr;32(2):261-5. PubMed PMID: 22370993.
- 67) Fiedorowicz JG, Coryell WH, Akhter A, **Ellingrod VL**. Cryptochrome 2 Variants, Chronicity, and Seasonality of Mood Disorders. *Psychiatric Genetics* (in press).
- 68) *Bly MJ, Thomas KLH, **Ellingrod VL**, Bishop JR. P-glycoprotein (ABCB1) Polymorphisms and Sexual Dysfunction in Patients with Depression and SSRI-Associated Sexual Side Effects. *The Journal of Sex and Marital Therapy* (in press)
- 69) Houston J, Kohler J, Bishop JR, **Ellingrod VL**, Ostbye KM, Zhao F, Conley R, Hoffmann VP, Fijal B. Pharmacogenomic Associations with Weight Gain in Olanzapine Treatment of Patients without Schizophrenia. *Psychiatry Res.* 2011 May 15;187(1-2):74-9. Epub 2010 Nov 20.
- 70) Prabhakar M, Haynes WG, Coryell WH, Chrischilles EA, Miller DD, Arndt S, **Ellingrod VL**, Warren L, Fiedorowicz JG. Clinical Variables Impacting Prescribing of Olanzapine, Quetiapine, and Risperidone. *Pharmacotherapy* 2011; 31(8): 806-812
- 71) **Ellingrod VL**, Taylor SF, Brook RD, Evans SJ, Zöllner SK, Grove TB, Gardner KM, Bly MJ, Pop-Busui R, Dalack G. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). *Schizophr Res.* 2011 Apr 18. [Epub ahead of print] PubMed PMID: 21504842, PMCID: 3139795
- 72) Houston J, Dharia S, Bishop JR, **Ellingrod VL**, Fijal B, Jacobson JG, Hoffmann VP. Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. *Psychiatry Res.* 2011 May 15;187(1-2):74-9. Epub 2010 Nov 20. PubMed PMID: 21095016.
- 73) Bishop JR, Miller DD, **Ellingrod VL**, Holman T. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in

treatment refractory schizophrenia. *Hum Psychopharmacol.* 2011 Feb 23. doi: 10.1002/hup.1163. [Epub ahead of print] PubMed PMID: 21344500.

- 74) Kang H, Smith M, Buckwalter KC, **Ellingrod V**, Schultz SK. Anxiety, depression, and cognitive impairment in dementia-specific and traditional assisted living. *J Gerontol Nurs.* 2010 Jan;36(1):18-30; quiz 32-3. doi: 10.3928/00989134-20091204-01. Epub 2010 Jan 12. PubMed PMID: 20047249; PubMed Central PMCID: PMC3005246.
- 75) *Thomas KL, **Ellingrod VL**, Bishop JR, Keiser MJ. A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach. *Psychopharmacol Bull.* 2010;43(1):11-22. PubMed PMID: 20581797.
- 76) Bishop JR, **Ellingrod VL**, Akroush M, Moline J (2009). The Association of Serotonin Transporter Genotypes and Selective Serotonin Reuptake Inhibitor (SSRI) Associated Sexual Side Effects: Possible Relationship to Oral Contraceptives *Hum Psychopharmacol*;24(3):207-15. PMID: 19204908
- 77) Calarge C, **Ellingrod VL**, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte J(2009). Variants of the Dopamine Receptor and Risperidone-Induced Hyperprolactinemia in Children and Adolescents *Pharmacogenet Genomics*;19(5):373-82.
- 78) Calarge C, **Ellingrod VL**, Zimmerman B, Acion L, Sivitz W, Schlechte J. Leptin promoter -2548A/G variants predict antipsychotic-associated weight gain in children *Psychiatr Genet.* 2009 Dec;19(6):320-7. PubMed PMID: 19873684; PubMed Central PMCID: PMC2919234.
- 79) **Ellingrod VL**, Miller DD, Taylor F (2008). Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677CTand 1298AC Polymorphism. *Schizophrenia Research* 98(1-3):47-54.
- 80) Smith M, Buckwalter KC, Kang H, Schultz SK, **Ellingrod VL** (2008). Tales from the field. What the nursing research textbooks will not tell you. *Applied Nursing Research*; 21: 232-236.
- 81) Smith M, Buckwalter KC, Kang H, Schultz SK, **Ellingrod VL** (2008). Dementia-Specific Assisted Living: Clinical Factors and Psychotropic Medication Use. *Journal of the American Psychiatric Nurses Association*; 14: 39-49.
- 82) Smith M, Buckwalter KC, Kang H, Schultz SK, **Ellingrod VL** (2008). Dementia Care in Assisted Living: Needs and Challenges. *Issues Ment Health Nurs.*;29(8):817-38.
- 83) *Bishop JR, Wang K, Moline J, **Ellingrod VL** (2007). Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. *Psychiatric Genetics*;17(6):358
- 84) *Worsham J, **Ellingrod VL**, Bishop JR (2007). Review of sexual dysfunction associated with antidepressant use. *Journal of the College of Psychiatric and Neurologic Pharmacists.* Available at: http://cpnp.org/_docs/news/20070126.pdf
- 85) **Ellingrod VL**, Bishop JR, Moline J, Miller D: Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia (2007). *Psychopharmacology Bulletin*; 40(1): 57-62.
- 86) Fiedorowicz JG, Moser DJ, Hynes SM, Beglinger LJ, Schultz SK, and **Ellingrod VL** (2007). L_A Allelic Heterozygosity of the 5HTTLPR Polymorphism is Associated with

Higher Cognitive Function and Lower Interpersonal Sensitivity. *Psychiatric Genetics*;17(1):3-4.

- 87) *Lin Ying-Chi, **Ellingrod VL**, Bishop JR, Moline J, Miller DD (2006). P-glycoprotein polymorphisms and olanzapine response in patients with schizophrenia. *Ther Drug Monit*; 28: 668-672.
- 88) *Bishop JR, **Ellingrod VL**, Moline J, Schultz SK (2006). Association between polymorphisms of the G-protein beta subunit (GNB3) and serotonin-2A receptor polymorphisms and sexual dysfunction in persons treated with an SSRI for depression. *Neuropsychopharmacology*;31(10):2281-2288.
- 89) *Bishop JR, **Ellingrod VL**, Moline J, Miller D (2006): Association analysis of G-protein Beta3 Subunit Gene (C825T) polymorphisms with clinical response or olanzapine or olanzapine related weight gain in persons with schizophrenia. *Med Sci Mon*; 12(2):BR47-50.
- 90) Schultz SK, Moser D, Bishop JR, **Ellingrod VL** (2005). Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. *Psychiatric Genetics*;15(4):305-6.
- 91) *Bishop JR, **Ellingrod VL**, Moline J, Miller D (2005). Association of polymorphisms in the *GRM3* gene response to olanzapine. *Schizophrenia Research*; 77(2-3):253-60.
- 92) Perry PJ, Argo TR, Carnahan RM, Lund BC, Holman TL, **Ellingrod VL**, Miller D (2005). The Association of Weight Gain and Olanzapine Plasma Concentrations. *Journal of Clinical Psychopharmacology*; 25(3):250-254.
- 93) **Ellingrod VL**, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman T, Miller DD (2005). Weight Gain Associated With The -759 C/T Polymorphism of the 5HT2C Receptor And Olanzapine. *Am J Med Genetics*: 134B; 76-78.
- 94) Miller DD, **Ellingrod VL**, Holman TL, Buckley PF, Arndt S (2005). Weight Gain Associated with the -759 C/T Polymorphism of the 5HT2C Receptor and Clozapine. *Am J Med Genetics*: 133B; 97-100.
- 95) Min, DI, **Ellingrod VL**, McLeod H, Marsh S (2004). Association of CYP3A5*3 Polymorphism with Cyclosporine Pharmacokinetics in Healthy Subjects. *Therapeutic Drug Monitoring*; 26: 524-528.
- 96) Weissman AM, Hartz AJ, Bentler S, Donohue M, **Ellingrod V**, Wisner KL (2004). Meta-analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. *American Journal of Psychiatry*. 161(6):1066-78.
- 97) **Ellingrod VL**, Miller D, Ringold JC, Perry PJ (2004). Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls. *Psychiatric Genetics*. 14(2):93-5.
- 98) **Ellingrod VL**, Perry PJ, Stille KA, Lund BL, Fleming F, Holman T, Miller DD (2003) 5HT2A Receptor Promoter Polymorphism, -1438G/A And Negative Symptom Response To Olanzapine In Schizophrenia. *Psychopharmacology Bulletin*; 37: 109-112.
- 99) Schultz SK, **Ellingrod V**, Turvey C, Moser D, Kutscher E, Arndt S (2002). Psychiatric Symptoms Among Nursing Home Residents: Relationships between Symptoms, Cognition and Daily Functioning. *Am J Psychiatry*; 160(3): 582-4.
- 100) **Ellingrod VL**, Perry PJ, Lund BL, Bever -Stille KA, Fleming F, Holman TL, Miller DD (2002). 5-HT2A and 5-HT2C receptor polymorphism responsible for predicting clinical response to the antipsychotic agent olanzapine. *J Clin Psychopharmacol*; 22:

554-60.

- 101) **Ellingrod VL**, Schultz SK, Arndt SA. (2002) Cigarette smoking, CYP2D6, and abnormal movements. *Pharmacotherapy*; 22(11); 1416-1419.
- 102) Min DI and **Ellingrod VL** (2002). The C3435T mutation in exon 26 of the human *MDR1* gene and cyclosporine pharmacokinetics in healthy subjects. *Therapeutic Drug Monitoring*; 24: 400-404.
- 103) **Ellingrod VL**, Miller DD, Schultz SK, Wehring H, Arndt S (2002). CYP2D6 Polymorphisms And Atypical Antipsychotic Weight Gain. *Psychiatric Genetics*; 12: 55-581.
- 104) **Ellingrod VL**, Schultz SK, Ekstam-Smith K, Kutscher E, Arndt S, Turvey C (2002). Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. *Pharmacotherapy*; 22: 1-5.
- 105) Turvey C, Schultz SK, Arndt SA, **Ellingrod VL**, Wallace R, Herzog R (2001). Caregiver reports of hallucinations and delusions in elderly aged 70 and older. *Intl Psychogeriatrics*; 13: 241-9.
- 106) Schultz SK, **Ellingrod V**, Fleming FW, Andreasen NC (2001) The Association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia. *Human Psychopharmacology*; 16: 273-277.
- 107) **Ellingrod VL**, Schultz, SK, and Arndt S (2000). Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. *Psychiatric Genetics*; 10: 9-11.
- 108) Van Dyke DC, **Ellingrod VL**, Berg MJ, Niebyl JR, Sherbondy AL, and Trembath DG (2000). Pharmacogenetic screening for susceptibility to fetal malformation in women: a reality for the future? *Obstetrics and Gynecological Survey. Ann Pharmacother*;34:639-645.
- 109) Long, TD, **Ellingrod VL**, Kathol RG, Christensen LE, Resch DS, and Perry PJ (2000). Lack of menstrual cycle effects on hypothalamic-pituitary-adrenal axis response to insulin-induced hypoglycemia. *Clinical Endocrinology*; 52 (6): 781-787.
- 110) Anfinson T, McKay S, Engel S, Locke C, Feldmann J, **Ellingrod V**, DeWitt B, Olson J, Caruth M (1999). Interdisciplinary team roles in a combined medical psychiatry treatment program. *Primary Psychiatry*; 6(7): 80-85
- 111) Yates WR, Perry PJ, MacIndoe JH, Holman T, **Ellingrod V** (1999): Psychosexual effects of three doses of testosterone cycling in normal men. *Biological Psychiatry*; 45: 254-260.
- 112) **Ellingrod VL**, Perry PJ, Yates WR, MacIndoe JH, Watson G, Arndt S, and Holman TL (1997). The effects of anabolic steroids on driving performance as assessed by the Iowa driver simulator. *Am J of Drug and Alcohol Abuse*; 23: 623-636.
- 113) MacIndoe JH, Perry PJ, Yates WR, Holman TL, **Ellingrod VL**, Scott SD (1997). Testosterone suppression of the HPT axis. *Journal of Investigational Medicine*; 45: 441-447.

Reviews

- 1) Pasternak AL, Ward KM, Luzum JA, **Ellingrod VL**, Hertz DL. Germline genetic variants with implications for disease risk and therapeutic outcomes. *Physiol Genomics*. 2017 Oct 1;49(10):567-581. doi:

10.1152/physiolgenomics.00035.2017.Epub 2017 Sep 8. Review. PubMed PMID: 28887371; PubMed Central PMCID: PMC5668651.

- 2) *Flowers SA, **Ellingrod VL**. The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management. *Pharmacotherapy*. 2015 Oct;35(10):910-6. doi: 10.1002/phar.1640. Review. PubMed PMID: 26497477.
- 3) **Ellingrod VL**. PharmGenEd™ Psychiatry I Module: Depression. <http://www.scivee.tv/node/25243>. Released on October 22, 2010 (275 views)
- 4) **Ellingrod VL**. Introduction to the CPNP 2010 Annual Meeting Poster Abstracts. *J Pharm Pract*. 2010 Apr;23(2):148. PubMed PMID: 21507810.
- 5) Thomas KL, **Ellingrod VL**. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. *Pharmacotherapy*. 2009 Jul;29(7):822-31. Review. PubMed PMID: 19558256.
- 6) Bostwick JR, Guthrie SK, **Ellingrod VL** (2009). Antipsychotic-Induced Hyperprolactinemia. *Pharmacotherapy*;29(1):64-73.
- 7) **Ellingrod VL** and Moline J (2007). Incorporating Pharmacogenomics into Practice. *Journal of Pharmacy Practice*; 20: 277-282.
- 8) Leckband SG, Bishop JR, **Ellingrod VL** (2007). Pharmacogenomics in Psychiatry. *Journal of Pharmacy Practice*;20: 252-264.
- 9) **Ellingrod VL** and Moline J (2007). Introduction to Pharmacogenomics. *Journal of Pharmacy Practice*;20: 203-205.
- 10) *Bishop JR and **Ellingrod VL** (2007). Metabotropic glutamate receptors as pharmacogenetic candidate genes in studies of current and future antipsychotic agents in schizophrenia. *Current Pharmacogenetics*; 5: 21-30.
- 11) *Bishop JR. **Ellingrod VL** (2004). Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. *Pharmacogenomics*. 5(5):463-77.
- 12) **Ellingrod VL** (1998). A Pharmacotherapy Review of Primary Obsessive Compulsive Disorder Literature. *Pharmacotherapy*; 18: 936-960.
- 13) **Ellingrod VL** and Perry PJ, Nefazodone: A new antidepressant, *Am J Health-Syst Pharm* 1995; 52: 2799-812.
- 14) **Ellingrod VL** and Perry PJ, Venlafaxine: A heterocyclic antidepressant, *Am J Hosp Pharm* 1994; 51: 3033-46.

Book and Book Chapters

- 1) DiPiro J, Yee G, Posey M, Haines S, Nolin T, and **Ellingrod VL** (2022). *Pharmacotherapy a Pathophysiological Approach*, 12th edition, McGraw Hill, Manhattan, NY.
- 2) Schwinghammer TL, DiPiro JT, **Ellingrod VL**, DiPiro CV (2020). *Pharmacotherapy Handbook*, 11th edition, McGraw Hill, Manhattan, NY.
- 3) DiPiro J, Yee G, Posey M, Haines S, Nolin T, and **Ellingrod V** (2019). *Pharmacotherapy a Pathophysiological Approach*, 11th edition, McGraw Hill, Manhattan, NY.
- 4) Humma LM, **Ellingrod VL**, Kolesar JM (2012). *Pharmacogenomics handbook*. Lexi-Comp. Hudson, Ohio.

- 5) **Ellingrod VL**, Bishop JR, Thomas K (2010). Pharmacogenomics of Psychiatry. In: Pharmacogenomics: Applications to Patient Care. ACCP, Kansas City.
- 6) Humma LM, **Ellingrod VL**, Kolesar JM (2005). Pharmacogenomics handbook. Lexi-Comp. Hudson, Ohio.
- 7) **Ellingrod VL**, Bishop JR (2004). Pharmacogenomics of the Central Nervous System. In: Pharmacogenomics: Applications to Patient Care. ACCP, Kansas City.
- 8) Humma LM, **Ellingrod VL**, Kolesar JM (2003). Pharmacogenomics handbook. Lexi-Comp. Hudson, Ohio.
- 9) **Ellingrod VL** (1999). Disorders affecting psychotropic absorption, metabolism and toxicity. Robinson R and Yates W (eds). In: Psychiatric Treatment of the Medically Ill. Marcel Dekker, New York, 459 – 478.

Letters to the Editor

- 1) Yates, WR, Perry PJ, and **Ellingrod V** (1996). Steroids (letter). Am J Psychiatry; 153: 12.
- 2) **Ellingrod VL** and Perry PJ (1996). Reassessment of nefazodone. Am J Health System Phar; 53: 2243-2344.

Podcasts

- 1) Newborn outcomes after prenatal exposure to individual antidepressants - Episode 67 by ACCP JOURNALS.
<https://anchor.fm/accp-jrnls/episodes/Newborn-outcomes-after-prenatal-exposure-to-individual-antidepressants---Episode-67-e1b01qn>.
- 2) Risk of adverse effects with sedative hypnotics and skeletal muscle relaxants - Episode 63. <https://anchor.fm/accp-jrnls/episodes/Risk-of-adverse-effects-with-sedative-hypnotics-and-skeletal-muscle-relaxants---Episode-63-e17av5j>
- 3) Pharmacotherapy Journals, Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability-Episode 34.
<https://podcasts.apple.com/us/podcast/potential-implications-gut-microbiota-in-drug-pharmacokinetics/id1449625721?i=1000485080292>
- 4) Current Psychiatry Psychcast, Precision Medicine and Mental Health: Implementing Pharmacogenomics Into your Practice.
<https://www.mdedge.com/podcasts/psychcast/precision-medicine-and-mental-health-implementing-pharmacogenomics-your-practice>

ABSTRACTS AND POSTER PRESENTATIONS:

- 1) Ward KM, Stringer KA, **Ellingrod VL**. Genetic and Metabolite Variability in Folate Metabolism Applied to an Insulin Resistance Model in Patients with Schizophrenia on Atypical Antipsychotics. Presented at the Association for Clinical and Translational Science, Washington DC, March 2019.
- 2) Perorazio T, Samuels E, Eakin B, Ianni P, **Ellingrod VL**. DIAMOND a Digital Platform for Workforce Development. Presented at the Association for Clinical and Translational Science, Washington DC, March 2019.

- 3) Ward KM, Stringer KA, **Ellingrod VL**. Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Presented at the American College of Neuropsychiatry, Hollywood, FL. December 2018.
- 4) Ward KM, Stringer KA, **Ellingrod VL**. Variable Free Fatty Acid Composition Associated with SREBF in Schizophrenia Participants Taking Atypical Antipsychotics. Presented at the American Society of Clinical Psychopharmacology, Miami, FL. May 2017.
- 5) Kolenda A, Grove TB, Burghardt KJ, **Ellingrod VL**. Investigating the Relationship Between Depression, Metabolic Syndrome, and DNA Methylation of the SLC35D3 gene region in Psychotic Disorders. University of Michigan Department of Psychology Research Forum, April 2017
- 6) Moll A, Kraal AZ, **Ellingrod VL**. Endothelial Nitric Oxide Synthase (eNOS), Metabolic Syndrome, and Cognition in Schizophrenia-Spectrum Disorders. University of Michigan Department of Psychology Research Forum, April 2017
- 7) Wiese KM, McHugh CE, Yeomans L, Flowers SA, Kraal AZ, Huddle B, Karnovsky A, **Ellingrod VL**, Stringer KA. Serum Metabolomics of Schizophrenia Participants by Fasting Insulin Reveals a Broad Metabolic Risk. Presented at the 3rd Metabolomics Conference, Boston, MA. May 2016.
- 8) Wiese KM, McHugh CE, Yeomans L, Flowers SA, Kraal AZ, Huddle B, Karnovsky A, **Ellingrod VL**, Stringer KA. Serum 1H-Nuclear Magnetic Resonance (NMR) metabolomics reveals differentiating phenotypes of variable cardiovascular risk in schizophrenia patients receiving atypical antipsychotics” Presented at the Australian Schizophrenia Conference, September 2015.
- 9) Kraal AZ and **Ellingrod VL**. Gender and antipsychotic differences in metabolic functioning in schizophrenia. Presented at the Australian Schizophrenia Conference, September 2015.
- 10) Flowers SA and **Ellingrod VL**. Endothelial functioning in schizophrenia patients treated with antidepressants. Presented at the Australian Schizophrenia Conference, September 2015.
- 11) Burghardt KJ and **Ellingrod VL**. DNA methylation of the RalA binding protein 1 gene and metabolic syndrome risk in schizophrenia” presented at the American College of Neuropsychopharmacology, Hollywood, FL December 2015
- 12) Wiese KM, McHugh CE, Yeomans L, Flowers SA, Kraal AZ, Huddle B, Karnovsky A, **Ellingrod VL**, Stringer KA. The pharmacometabolomics of metabolic syndrome in schizophrenia. Presented at the College of Neurologic and Psychiatric Pharmacists meeting April 2015
- 13) Dougherty R, Kraal AZ, Ellingrod VL. The unique impacts of COMT gene variability by sex on social functioning. Presented at the International Congress on Schizophrenia Research, March 2015.
- 14) Grove TB, **Ellingrod VL**, Taylor SF. Folate pharmacogenomics, endothelial function, and neurocognition in schizophrenia spectrum disorder. Presented at the Schizophrenia International Research Society Meeting, Florence, Italy, April 2014 – **Finalist for Best Poster Award**
- 15) Burghardt KJ, Grove TB, **Ellingrod VL**. Global Methylation Levels of Schizophrenia Subjects Supplemented with Folate: A Pilot Stud. Presented at the Schizophrenia International Research Society Meeting, Florence, Italy, April 2014 – **Finalist for Best Poster Award**

- 16) Burghardt, KJ and **Ellingrod VL**. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. Presented at the Pharmacogenomics in Psychiatry Meeting, Hollywood, Florida, June 2013
- 17) Burghardt, KJ and **Ellingrod VL**. Pharmacometabolomics of Atypical Antipsychotics in Bipolar Disorder: An Untargeted Approach. Presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 2013
- 18) **Ellingrod VL**, Grove TB, Burghardt KJ, Taylor SF. Attenuation of Metabolic Consequences from Atypical Antipsychotic Use in Schizophrenia: Folate Supplementation and the Role of Pharmacogenomics. Presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 2013
- 19) Burghardt KJ, Pop-Busui R, Bly MJ, Grove TB, Taylor SF, **Ellingrod VL**. Brain-Derived Neurotrophic Factor (*BDNF*) 66 Val/Met Polymorphism, Statin Use and Insulin Resistance in the Schizophrenia and Bipolar Populations. Presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 2012
- 20) Burghardt, KJ and **Ellingrod VL**. *BDNF* Met polymorphism, statin use and insulin resistance measures in Bipolar and Schizophrenia population. Presented at the Pharmacogenomics in Psychiatry Meeting, New York, New York, April 2012
- 21) Ellingrod VL, Grove TB, Taylor SF. Cardiovascular Effects of Folate Supplementation in Schizophrenia: An Interim Analysis. Presented at the American College of Neuropsychopharmacology Meeting, Waikoloa, Hawaii, December 2011
- 22) Bishop JR, **Ellingrod VL**, Akroush M, Patel S, Rubin LH. Association between LEP - 2548 (rs7799039) and obesity during antipsychotic treatment. *Schizophrenia Bulletin* 2011; 37(suppl1): 82.
- 23) Bishop JR, **Ellingrod VL**, Akroush M, Patel S, Rubin LH. Association between LEP - 2548 (rs7799039) and obesity during antipsychotic treatment. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, May 2011, Phoenix, Arizona (Encore Presentation)
- 24) Chae SS, Bishop JR, Patel S, **Ellingrod VL**. Analysis of glutamate system genes with SSRI-associated sexual dysfunction. Presented at the American Society of Health Systems Pharmacy Annual Meeting, December 2010, Anaheim, California
- 25) Stringer KA, **Ellingrod VL**, Kong FM, Yuan S, Cai X, Standiford TJ. Angiotensin Converting Enzyme (ACE) Insertion (I)/Deletion (D) Polymorphism and Tissue Plasminogen Activator (tPA) -7351 C/T enhancer Single Nucleotide Polymorphism (SNP) are Associated with Sepsis Induced Actual Lung Injury (ALI). *Am J Resp Crit Care Med* 2010
- 26) Houston J, Dharia S, Bishop JR, **Ellingrod VL**, Fijal B, Jacobson JG, Hoffmann VP. Replicated Association of single nucleotide polymorphisms in the *DRD2* and *ANKK1* genes with prolactin increases in olanzapine-treated women. *Biological Psychiatry* 2010; 67(9): 245S.
- 27) "DNA Methylation Differences in Relation To Metabolic Syndrome and Atypical Antipsychotic Use (AAP) in a Schizophrenia Population Receiving Antipsychotics" Presented at the American College of Neuropsychopharmacology Meeting, December 2009, Ft. Lauderdale, Florida.
- 28) Bishop JR, Miller DD, **Ellingrod VL**, Holman T. Association between *GRM3* and *GRIN2B* gene variants and symptoms in treatment refractory schizophrenia. *Schizophrenia Bulletin* 2009; 35(suppl 1): 318.
- 29) Bishop JR, Miller DD, **Ellingrod VL**, Holman T. Association between *GRM3* and

GRIN2B gene variants and symptoms in treatment refractory schizophrenia.
Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting,
April 2009. Jacksonville, Florida (encore presentation)

- 30) "A pharmacogenetic investigation of Beta-1 Receptor (*ADRB1*) variants and Selective Serotonin Reuptake Inhibitor (SSRI) associated side effects". Presented at the New Clinical Drug Evaluation Unit (NCDEU) Meeting, June 2009, Ft. Lauderdale, Florida.
- 31) "Association Between the Brain Derived Neurotrophic Factor (BDNF) Val66Met Variant And Insulin Resistance in Bipolar Subjects Receiving Atypical Antipsychotics". Presented at the New Clinical Drug Evaluation Unit (NCDEU) Meeting, June 2009, Ft. Lauderdale, Florida.
- 32) "Relationship Between The Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Brain Derived Neurotrophic Factor (BDNF) Val66Met Variants And Metabolic Complications Seen With Antipsychotic Use In Schizophrenia Subjects." Presented at the American College of Neuropsychopharmacology Meeting, December 2008, Scottsdale, Arizona
- 33) "Serotonin transporter promoter insertion/deletion subtypes (LA/LG), intron 2 VNTR, and Ile425 polymorphisms and SSRI-associated sexual dysfunction". Presented at the Pharmacogenetics in Psychiatry Annual Meeting, 2007, New York, New York
- 34) **Ellingrod VL**, Miller DD, Taylor F, Moline J, Holman T, Kerr J. Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677CT Polymorphism. College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting, 2007, Colorado Springs, Colorado
- 35) Bishop JR, **Ellingrod VL**, Moline J, Miller D. The dopamine-2 receptor *TaqAI* polymorphism, prolactin elevation, and bone mineral density in persons with schizophrenia. College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting 2006, Baltimore, Maryland
- 36) Bishop JR, **Ellingrod VL**, Moline J, Schultz SK, Clayton AH. The serotonin transporter promoter insertion/deletion in patients with depression and selective serotonin reuptake inhibitor (SSRI) associated sexual side-effects. Pharmacogenetics in Psychiatry Annual Meeting 2006, New York, New York
- 37) **Ellingrod VL**, Bishop JR, Moline, J, Schultz SK, Ekstam-Smith K. 5HT2CR -759C/T Polymorphism of and Glucose Control in the Elderly Receiving Antipsychotics. *Pharmacotherapy* 2006; 25(10): 1513
- 38) **Ellingrod VL**, Bishop JR, Moline J, Miller D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. *Pharmacotherapy* 2006; 25(10): 1479
- 39) Bishop JR, **Ellingrod VL**, Moline J, Miller D. Association of polymorphisms in the *GRM3* gene response to olanzapine. *Pharmacotherapy* 2006; 25(10): 1480
- 40) Miller J, **Ellingrod VL**, Bishop JR. Polymorphisms Of The *GRIN2B* Gene And Olanzapine Response. Presented At The Pharmacy Student Research Conference, Western Region 2005. University of Colorado Health Sciences Center, Denver, Colorado
- 41) Lin YC, **Ellingrod VL**, Moline J, Miller DD. *GRM3* Gene Polymorphisms and Clozapine Response Predictors In Patients With Schizophrenia. Presented At the 6th Annual Clinical and Administrative Division Research Symposium, University of Iowa College of Pharmacy, April 25, 2005. Iowa City, Iowa - **Finalist for best poster award**

- 42) Bishop JR, **Ellingrod VL**, Moline J, Miller DD. Association between the polymorphic GRM3 gene and olanzapine response. Presented at the 4th Annual Pharmacogenetics in Psychiatry Meeting, April 15-16, 2005. New York, New York
- 43) Bishop JR, **Ellingrod VL**, Moline J, Schultz SK. Association between polymorphisms of the G-protein beta subunit (*GNB3*) and serotonin-2A receptor polymorphisms and sexual dysfunction in persons treated with an SSRI for depression. Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 10-13th, 2005. San Diego, California - **Recipient of the Best Poster Award for the Work in Progress Category.**
- 44) Bishop JR, **Ellingrod VL**, Moline J, Perry PJ (2004). The association of metabotropic glutamate receptor 3 (GRM3) gene polymorphism with clinical response to olanzapine. Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 22-25th, 2004. Chicago, Illinois
- 45) Miller DD and **Ellingrod VL** (2003). Weight Gain Associated with the -759 C/T Polymorphism of the 5HT_{2C} Receptor and Clozapine. Presented at the Pharmacogenetics in Psychiatry Meeting, April 11-12th, 2003. New York, New York
- 46) Schultz SK, Ponto LB, Magnotta V, Moser DJ, **Ellingrod VL**, Watkins GL, Hichwa RD, O'Leary DS. Assessment of cerebrovascular reserve capacity among person with mild cognitive impairment with [150] water positron emission tomography. Presented at the American College of Neuropsychopharmacology Meeting 2002, Puerto Rico
- 47) Min DI and **Ellingrod VL**. The effect of CYP3A4*1B 5' promoter region polymorphism on cyclosporine pharmacokinetics among healthy volunteers. *Pharmacotherapy* 2002; 22: 1362
- 48) Weissman AM, Hartz AJ, Bentler S, Donohue M, **Ellingrod V**, Wisner KL (2001). Meta-analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. Reprinted in *Psiquiatria y Salud Integral* from the American Psychiatric Association 2001
- 49) **Ellingrod VL**, Perry PJ, Stille KA, Lund BL, Fleming F, Holman T, Miller DD. 5HT_{2A} Receptor Promoter Polymorphism, -1438G/A And Negative Symptom Response To Olanzapine In Schizophrenia. *Pharmacotherapy* 2002; 22 (3)
- 50) Weissman AM, Hartz AJ, Bentler S, Donohue M, **Ellingrod V**, Wisner KL. Meta-analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. Presented at the American Psychiatric Association 2002
- 51) Schultz SK, **Ellingrod V**, Turvey C, Moser D, Arndt S. A longitudinal study of cognitive status, daily living skills, and psychiatric symptoms in the nursing home setting. Presented at the American College of Neuropsychopharmacology 2001 Annual Meeting, Hawaii
- 52) **Ellingrod VL**, Min DI, Herman C. Ethnic differences in the distribution of p-glycoprotein among Caucasians and African Americans. *Pharmacotherapy* 2001; 21: 203
- 53) Min DI, **Ellingrod VL**, Herman C. The relationship between P-glycoprotein genotypes and cyclosporine pharmacokinetic parameters among healthy volunteers. *Pharmacotherapy* 2001; 21: 267
- 54) Schultz SK, **Ellingrod VL**, Ekstam-Smith K, Fleming FW, Filips J, Andreasen NC. Schizophrenia and aging: gender differences in symptom characteristics. *Schizophrenia Research* 2001; 49 21

- 55) Perry PJ, **Ellingrod VL**, Lund BC, Bever-Stille K, Miller DD. 5-HT_{2A} and 5-HT_{2C} Receptor Polymorphisms And Predicting Clinical Response to Olanzapine. *Schizophrenia Research* 2001; 49: 78
- 56) **Ellingrod VL**, Miller DD, Schultz SK, Wehring H, Arndt S. Polymorphisms of CYP2D6 as a risk factor for weight gain with olanzapine. *Schizophrenia Research* 2001; 49:283-284.
- 57) **Ellingrod VL**, Schultz SK, Ekstam-Smith K, Kutscher E, Arndt S, Turvey C. Comparison Of Atypical Antipsychotics In Elderly Dementia Patients With Psychosis. Presented at the American College of Clinical Pharmacy Annual Meeting October 5-8,2000, Los Angeles, California,
- 58) Schultz SK, **Ellingrod V**, Moser D, Arndt S. Effects of psychiatric symptoms on functional skills in long-term care patients. Presented at the New Clinical Drug Evaluation Unit (NCDEU) 40th Annual Meeting May 30-June 2, 2000, Boca Raton, Florida
- 59) **Ellingrod VL**, Schultz SK, Arndt S, Perry PJ, Andreasen NC, Holman TL, and Fleming F. Association Between Cytochrome P4502D6 (CYP2D6) Genotype, Neuroleptic Exposure, And Abnormal Involuntary Movement Scale (AIMS) Score. *Schizophrenia Research* 1999; 36: 90
- 60) Bever KA, Perry PJ, **Ellingrod VL**, Miller DD, Holman TA, Fleming F. 5HT_{2A} and 5HT_{2C} receptor polymorphism responsible for predicting clinical response to the antipsychotic agent olanzapine. *Pharmacotherapy* 1998; 18(5): 1175
- 61) **Ellingrod VL**, Holman TL, Perry PJ, Fleming F, and Andreasen N. Cytochrome P450IID6 (CYP2D6) Genotype in Cigarette Smoking and Non-Cigarette Smoking Patients with Schizophrenia. *Pharmacotherapy* 1997; 17:1100-1101
- 62) **Ellingrod, VL**, Perry PJ and Crowe RR. Polymorphism of cytochrome P450IID6 (CYP2D6) in schizophrenics and normal controls. *Psychiatric Genetics* 1996; 6: 139
- 63) **Ellingrod VL**, Perry PJ, and Kuperman S. Genetic Markers and Drug Metabolism in Children with Tricyclic Induced EKG Changes. Presented at the American College of Clinical Pharmacy Annual Meeting 1996 , Nashville, Tennessee
- 64) Yates W, Perry P, MacIndoe J, **Ellingrod V**, Holman T. Can Anabolic Steroids Be Studied in a Randomized and Blinded Design?. Presented at Society of Biological Psychiatry Annual Meeting, May 1995
- 65) **Ellingrod VL**, Perry PJ, Crowe RR, Chatterjee P, Holman TL, and Fleming FW. Genetic Markers and Drug Metabolism in Patients Receiving Psychotropic Drugs. Presented at the European Conference on Specificity and Variability in Drug Metabolism 1995, Besançon, France
- 66) Scott SD, Perry PJ, MacIndoe JH, Yates WR, Holman TL, and **Ellingrod VL**. Pharmacodynamic Effects of Supraphysiologic Doses of Testosterone Cypionate (TC) on the Pituitary-Testicular Axis (PTA) of Young Healthy Male Volunteers: Preliminary Report. Presented at the European Conference on Specificity and Variability in Drug Metabolism 1995, Besancon, France

PLATFORM AND INVITED PRESENTATIONS

1. "Applying Pharmacogenomics to Clinical Practice" Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, March 2021.

2. "The Role Of Folate Pharmacogenomics On Inflammatory And Metabolic Complications From Atypical Antipsychotic Use In Schizophrenia" Presented at the Precision Medicine World Conference, Menlo Park, CA, February 2020.
3. "Advancing Research at Your Institution by Using Clinical and Translational Science Award (CTSA) Resources" Presented at the American Association of Colleges of Pharmacy, Interim Meeting, San Juan, Puerto Rico, February 2020.
4. "Pharmacogenomics Implementation in Psychiatry", Presented at the University of Michigan Florida Seminars, West Palm Beach, FL, February 2020.
5. "Pharmacogenomics Implementation in Psychiatry", Presented at the American Society of Health Systems Pharmacy Annual Meeting, Anaheim, CA, December 2019
6. "Folate's impact on inflammation and cardiovascular outcomes in Schizophrenia –A placebo controlled trial" Presented at the International Society for Nutritional Psychiatry, London, England, October 2019.
7. "Microbiota Gut Brain Axis a Research Update" Session Chair at Society of Biological Psychiatry, Chicago, IL, May 2019.
8. " Innovations in Education for Clinical and Translational Research" Presented at the Association for Clinical and Translational Science, Washington DC, March 2019.
9. "Precision Medicines: The Pharmacy Perspective". Presented at the University of Michigan Health Sciences Luncheon, Ann Arbor, MI, September 2018.
10. "Precision Medicines and Dentistry". Presented at the University of Michigan College of Dentistry, Ann Arbor, MI, October 2018.
11. "Matters of Life: Dissecting Mechanism of Metabolic Burden in Psychosis, and Moving to Novel Clinical Investigations" Society of Biological Psychiatry, Atlanta, GA, May 2018.
12. "Challenges and Opportunities in Translational Research". Presented as part of the American Association of Colleges of Pharmacy Catalyst Program. Washington DC, April 2018.
13. "Creating a New Definition of Career Success in Clinical and Translational Research". Presented at the Association of Clinical and Translational Science Meeting, April 2017.
14. "Microbiome and metabolic disease: the challenges of using microbial therapeutics for disease management. Presented by Dr. Stephanie Flowers, Ellingrod Post Doctorial Fellow at the American College of Clinical Pharmacy Annual Meeting October 2016.
15. "Metabolic Disease Risk: Interaction between Medication and the Microbiome". Presented by Dr. Stephanie Flowers, Ellingrod Post Doctorial Fellow at the American College of Neuropsychopharmacology, December 2016
16. "Creating a New Definition of Career Success in Clinical and Translational Research". Presented at the Association of Clinical and Translational Science Meeting, April 2016.
17. "Impact of OPRM1 on metabolic consequences of atypical antipsychotic use. Presented at the Pharmacogenomics in Psychiatry Meeting and Molecular Psychiatry Meeting, September 2016.
18. "Clinical Applications of Pharmacogenomics in Psychiatry" Presented at the University of Texas at Austin, October 2015.

19. "Using the Metabolome to understand the cardiovascular impact of antipsychotics. Society of Biological Psychiatry, April 2015.
20. "Gender and antipsychotic differences in metabolic functioning in schizophrenia" Presented by Ms. Zarina Kraal, Ellingrod PhD Candidate, at the International Congress on Schizophrenia Research, March 2015
21. "Folate's Role in Schizophrenia" Presented at Wayne State University, March 2015
22. "Folate supplementation and antipsychotic cardiovascular complications" Presented at The Ohio State Department of Psychiatry and Nationwide Children's Hospital of Ohio, December 2014
23. "Drug Repurposing and Emerging Adjunctive Treatments for Schizophrenia", Symposium Chair at Schizophrenia International Research Society Meeting, American College of Neuropsychopharmacology, December 2014
24. "Personalized use of SSRIs: how polymorphisms influence therapeutic choices" Presented at the American College of Clinical Pharmacy meeting, October 2014
25. "Folate for Improvements in Cardiovascular Complications in Schizophrenia" Presented at the World Psychiatric Congress, Madrid, Spain, September 2014
26. "Metabolic syndrome in mental illness and the role of folate pharmacogenomics" Presented at Progenity, LLC, Ann Arbor, MI August 2014
27. "My career path to academia and what keeps me here: lessons learned". Presented at the University of Minnesota College of Pharmacy, Minneapolis, Minnesota, May 2014
28. "Drug Repurposing and Emerging Adjunctive Treatments for Schizophrenia", Symposium Chair at Schizophrenia International Research Society Meeting, Florence, Italy, April 2014
29. "Pharmacogenomics in Psychiatry- are we on our way to personalized medicine?" Presented at the University of Michigan-Israel Partnership Symposium, Ann Arbor, Michigan, October 2013
30. "The New Era of Personalized Medicine and Companion Diagnostics". Presented at the Annual Pharmacy Lecture, University of Michigan, Ann Arbor, Michigan, October 2013
31. "Metabolic syndrome in Mental Illness and the role of folate pharmacogenomics" Presented at Purdue College of Pharmacy, Grand Rounds, Indianapolis, Indiana, September 2013
32. "Attenuation of Metabolic Consequences from Atypical Antipsychotic Use in Schizophrenia: Folate Supplementation and the Role of Pharmacogenomics" Presented at the Pharmacogenomics in Psychiatry Meeting, Hollywood, Florida, June 2013
33. "Atypical Antipsychotic use: how do we reduce harm in the college aged mental health population? Presented at the American psychiatric Association Meeting, San Francisco, California, May 2013
34. "Pharmacogenetic and Dietary Predictors of Antipsychotic Associated Metabolic Syndrome and Endothelial Functioning." Presented at the University of Michigan Department of Psychiatry, Grand Rounds, Ann Arbor, Michigan, January 2013
35. "Pharmacogenetic and Dietary Predictors of Antipsychotic Associated Metabolic Syndrome and Endothelial Functioning" Presented at the University of Tennessee, College of Pharmacy, Memphis, Tennessee, May 2012.

36. "The Influence of Metabolic Syndrome, Physical Activity, and Genotype on Catechol-O-Methyl Transferase Promoter-Region Methylation in Schizophrenia" Presented at the Pharmacogenomics in Psychiatry Meeting, New York, New York, April 2012
37. "Show Me the Money – Grant Writing, Funding Sources and Grant Review Process" presented at the American College of Clinical Pharmacy Annual Meeting October 17, 2011, Pittsburgh, Pennsylvania,
38. "Endothelial Functioning, Pharmacogenetics Factors and Omega 3 Fatty Acids in Schizophrenia Subjects Receiving Antipsychotics" Presented at the Adipogenic and Metabolic Effects of Antipsychotic Drugs Conference, July 11-12, 2011, Newark, NY
39. "Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Catechol-O-Methyltransferase (COMT) Val158Met Variants And Endothelial Functioning In Schizophrenia Subjects Treated With Antipsychotics". Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, Phoenix, Arizona, May 2011.
40. "Endothelial Functioning and Omega 3 Fatty Acids in Schizophrenia Subjects Receiving Antipsychotics" Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, Phoenix, Arizona, May 2011.
41. "Endothelial Functioning and Omega 3 (n3) Fatty Acids in Schizophrenia Subjects Receiving Antipsychotics "Presented at the International Congress on Schizophrenia Research (ICOSR) Meeting, Colorado Spring, April 2011, Colorado
42. "Effects of Folate Supplementation in Atypical Antipsychotic Linked Metabolic Outcomes: An Interim Analysis" Presented at the International Congress on Schizophrenia Research (ICOSR) Meeting, April 2011, Colorado Spring, Colorado
43. "How to initiate your Research program Writing Specific Aims, Mentoring, K-Awards, And The Grant Review Process" presented at Touro University, February 2011, California,
44. "Faculty Orientation and Development Workshop" presented at at Midwestern University College of Pharmacy, January 2011, Pomona, California,
45. "Show Me the Money – Grant Writing, Funding Sources and Grant Review Process" Presented at the American College of Clinical Pharmacy Annual Meeting October 2010, Austin, Texas
46. PharmGenEd™ Psychiatry I Module: Depression. <http://www.scivee.tv/node/25243>. Released on October 22, 2010 (275 views)
47. "Continued Professional Development" Presented at the Michigan Society of Health Systems Pharmacy Residency Meeting, June 2010, Lansing, Michigan
48. "Mediating Relationships Between Atypical Antipsychotic Associated Metabolic Syndrome, Inflammation, and Folic Acid Metabolism" Presented at the American College of Neuropsychopharmacology Meeting, Miami Beach, Florida, December 2010,
49. "A Pilot Examination of Endothelial Function in Schizophrenia" Presented at the Michigan Institute for Clinical Research Annual Research Symposium, Ann Arbor, Michigan, October 1, 2010.
50. "Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Catechol-O-Methyltransferase (COMT) Val158Met Variants And Endothelial Functioning In Schizophrenia Subjects Treated With Antipsychotics" Presented at the Pharmacogenetics in Psychiatry Meeting, April 2010 New York, New York

51. "Pharmacogenomics at Michigan" Presented at the University of Michigan Depression Center Colloquium. February 2010, Ann Arbor, Michigan
52. "Funding for PharmD PhD programs" Presented at the Pharmacy Clinical Sciences, PhD Summit. November 2009, Los Angeles, California
53. "Pharmacogenetics of Folic Acid Metabolism and Metabolic Disturbances in Schizophrenia" Presented at the World Congress of Psychiatric Genetics Meeting, November 2010, San Diego, California
54. "Pharmacogenomics and integration into clinical practice" Presented at the Midwest Psychopharmacology Update, October 2009, Cincinnati, Ohio
55. "New Innovations and Clinical Applications of Genomics" Plenary Speaker at the American College of Clinical Pharmacy Spring Forum, April 2009, Orlando, Florida.
56. "Pharmacogenomics Primer and Update" Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 2009, Florida
57. "Pharmacogenetics of Folic Acid Metabolism and Metabolic Disturbances in Schizophrenia" Presented at the International Congress of Schizophrenia Research Meeting, March 23, 2009, San Diego, California
58. "Using Pharmacogenetics to Dissect Antipsychotic Metabolic Complications" Presented at the University of Iowa Research Rounds, February 2, 2009, Iowa City, Iowa
59. "Pharmacogenetics of Antipsychotic Associated Metabolic Complications in Schizophrenia" Presented at the American Association of Pharmaceutical Sciences Meeting, November 11, 2008, Atlanta, Georgia.
60. "Pharmacogenomics and the role of biomarkers in schizophrenia treatment" Presented at the 1st Annual Meeting of the Schizophrenia International Research Society, June 2008, Venice, Italy
61. "Using Pharmacogenomics in the Clinic" Presented as part of the University of Michigan Depression Center Colloquium Series. December 2007, Ann Arbor, Michigan.
62. "Using Pharmacogenomics in our Quest for Individualized Medicine: where do we stand and where we are going?" Presented at the South Dakota State University 17th annual Pharmacy Research Presentations and Convocation, October 22, 2007, Brookings, South Dakota
63. "Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677CT Polymorphism" Presented at the Pharmacogenomics in Psychiatry Meeting, April 13, 2007, New York, New York
64. "Application of Pharmacogenomics to Clinical Practice in Psychiatric Patients" Presented at the 18th Annual Psychiatric Pharmacotherapy Update, The University of Texas at Austin, October 21, 2006, Austin, Texas
65. "Pharmacogenomics in Psychiatry" Presented at the American College of Clinical Pharmacy, Ohio Chapter Annual Meeting, October 11, 2006, Cleveland, Ohio
66. "Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia" Presented at the 5th Annual Pharmacogenetics in Psychiatry Meeting, April 8, 2006, New York, New York.

67. "One Size Does Not Fit All – The Promise of Pharmacogenetics" Presented at the Iowa Pharmacy Association Educational Expo, January 28, 2006, Des Moines, Iowa
68. "Pharmacogenomics" Presented at the Current Topics in Allergy and Clinical Immunology Conference for the University of Iowa Carver College of Medicine, October 28, 2005, Iowa City, Iowa
69. "Pharmacogenomics of Schizophrenia Treatment" Presented as part of the Rennebohm Symposium at the University of Wisconsin, College of Pharmacy, September 20-22, 2005, Madison, Wisconsin
70. "The Pharmacogenetics of Schizophrenia Treatment" Presented at the University of Michigan College of Pharmacy Research Seminar, April 22, 2005, Ann Arbor, Michigan
71. "Clinical Applications of Genetics in the Treatment of Schizophrenia." Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 11, 2005. San Diego, California
72. "Breakout session: Meet the experts: How to write a research grant" Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 12, 2005. San Diego, California
73. "Significant Paper in Psychiatry" Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting, October 25, 2004. Dallas, Texas
74. "Pharmacogenomics in Psychiatry" Presented as Grand Rounds, Evanston Northwestern Health Care Department of Psychiatry, June 15, 2004, Evanston, Illinois
75. "Pharmacogenetics and Schizophrenia" Presented as the Young Investigator Lectures at the ACCP Spring Meeting, April 27, 2003 Palm Springs, California
76. "Psychopharmacology Part 1" Presented at the Geriatric Psychiatry Seminar, Department of Psychiatry, College of Medicine, February 25, 2003, Iowa City, Iowa
77. "Pharmacogenomics in Psychiatry: a review and update" Presented at the 8th Annual Midwest Neuro Psychiatric Pharmacy Conference, November 1, 2002, Cleveland, Ohio
78. "Treatment of Dementia" Presented at the Training to Enhance Service Delivery to Older Adults with Mental Illness, University of Iowa College of Medicine, Department of Psychiatry and College of Nursing, August 25, 2002, Iowa City, Iowa
79. "The Pharmacists' Role in Monitoring Antipsychotic Therapy" Presented at the Iowa Pharmacy Association Meeting, June 21, 2002, Des Moines, Iowa
80. "New Findings and Therapies in Psychiatric Pharmacy" Presented at the ACCP Psychiatry Preparatory Course, April 9, 2002, Savannah, Georgia
81. "New Practices in Psychiatric Pharmacy" Presented at the ACCP Psychiatry Preparatory Course, April 9, 2002, Savannah, Georgia
82. "Substance Abuse and Pain Disorders: A Case Based Lecture" Presented at the ACCP Psychiatry Preparatory Course, April 21, 2001, Salt Lake City, Utah
83. "Eating and Personality Disorders: A Case Based Lecture" Presented at the ACCP Psychiatry Preparatory Course, April 21, 2001, Salt Lake City, Utah,
84. "Dementia, Delirium, and Agitation: A Case Based Lecture" Presented at the ACCP Psychiatry Preparatory Course, , April 20, 2001, Salt Lake City, Utah

85. "Sexual Side Effects of Antidepressants" Presented at the University of Iowa College of Medicine's Women's Mental Health Through the Life Cycle: Mood, Food, and Sex, March 30, 2001 Iowa City, Iowa
86. "Differentiating Dementias for Appropriate Treatment" Presented at the American Pharmaceutical Association 148th Annual Meeting and Exposition, March 17, 2001, San Francisco, California
87. "Pharmacotherapy in the Elderly. Are we really doing our best?" Presented at the Evanston Health Care Conference, October 7, 2000, Evanston, Illinois
88. "Eating and Personality Disorders: A Case Based Lecture" Presented at the ACCP Psychiatry Preparatory Course, June 10, 2000, St. Louis, Missouri
89. "Dementia, Delirium, and Agitation: A Case Based Lecture" Presented at the ACCP Psychiatry Preparatory Course, June 10, 2000, St. Louis, Missouri
90. "New Treatments for Brain Disorders" Presented to Linn County Alliance for the Mentally Ill, May, 2000, Cedar Rapids, Iowa
91. "Herbal use in the Elderly", Presented at the Center on Aging, Graduate Seminar series, University of Iowa, Center on Aging, May 10, 2000, Iowa City, Iowa
92. "Psychotropic Drug Interactions" Presented to Nurses and Nursing students on Medical Psychiatry Unit, November 1999, University of Iowa Hospitals and Clinics, Iowa City, Iowa
93. "Association Between Cytochrome P4502D6 (CYP2D6) Genotype, Neuroleptic Exposure, And Abnormal Involuntary Movement Scale (AIMS) Score". Encore Poster Presentation at American College of Clinical Pharmacy Annual Meeting, October 1999, Kansas City, Missouri
94. "Psychopharmacology Update 1999" Presented at the Iowa Pharmacy Association Meeting, June 11, 1999, Iowa City, Iowa
95. "Treatment of Depression in Primary Care" Presented at the College of Pharmacy Continuing Education Fall Seminar. University of Iowa, College of Pharmacy, October 9, 1998, Iowa City, Iowa
96. "Neuroleptic Malignant Syndrome: A Variant of Drug Induced Lethal Catatonia" Presented at the Department of Psychiatry Grand Rounds. University of Iowa, College of Medicine, Department of Psychiatry, September 22, 1998, Iowa City, Iowa
97. "Depression and Therapy" Presented at the Internal Medicine Core Conference for Internal Medicine Resident Physicians, University of Iowa, College of Medicine, December 29, 1997, Iowa City, Iowa
98. "Polymorphism of cytochrome P450IID6 (CYP2D6) in Schizophrenics and Normal Controls". Encore Poster Presentation at American College of Clinical Pharmacy Annual Meeting, November 1999, Phoenix, Arizona.
99. "Psychotropic Agents" Presented at the College of Nursing's Pharmacology Update for Advanced Practice Nurses, September 30, 1997, Iowa City, Iowa
100. "Genetic Polymorphism in the Serotonin 5HT2A and 5HT2C Receptors and Prediction of Response to Clozapine" presented at the University of Iowa College of Pharmacy Clinical Pharmacy Seminar (46: 280), March 12, 1997. Iowa City, Iowa
101. "Overview of Drug Metabolism in the Elderly", Presented at the 13th Annual Mental Health Nursing Conference, October 9-10, 1996, Iowa City, Iowa

102. "Psychopharmacology Drugs and the Elderly", Presented at the 13th Annual Mental Health Nursing Conference, October 9-10, 1996, Iowa City, Iowa
103. "Pharmacotherapy of Obsessive Compulsive Disorder" Presented at the Psychiatry Postgraduate Conference of the Iowa Psychiatric Society, September 20-21, 1996, Cedar Rapids, Iowa
104. "Genetic Markers and Drug Metabolism in Children with Tricyclic Induced EKG Changes", Presented to Clinical Pharmacy Faculty, and Pharm.D. Candidates, University of Iowa, College of Pharmacy, October 30, 1995, Iowa City, Iowa
105. "Update on Serotonin Reuptake Inhibitors and Drug Interactions", presented to Psychiatrists and Pharmacists in the Waterloo, Iowa area, October 18, 1995, Waterloo, Iowa
106. "Psychopharmacology Update", presented at the 12th Annual Mental Health Nursing Conference, October 10-11, 1995, Iowa City, Iowa
107. "Genetic Markers of Drug Metabolism in Patients Taking Psychotropic Medications", Presented at the Midwest Regional Residency Conference, April 29, 1995, Stillwater, Minnesota
108. "Psychoendocrinology of Anabolic Steroid Abuse: Research Update", Presented to Clinical Pharmacy Faculty, and Pharm.D. Candidates, University of Iowa, College of Pharmacy, October 1994, Iowa City, Iowa
109. "Pathogenesis and Treatment of Bacterial Meningitis", presented to Clinical Pharmacy Faculty, Staff and Pharm.D. Candidates, University of Minnesota Hospital and Clinics, March 1994, Minneapolis, Minnesota
110. "Carnitine for the Use of Deficiency, and Prevention of Valproate Hepatotoxicity", presented to Clinical Pharmacy Faculty, Staff, and Pharm.D. Candidates, United Hospital, November 1993, St. Paul, Minnesota
111. "Augmentation of Treatment Resistant Depression", presented to Clinical Pharmacy Faculty, Staff and Pharm.D. Candidates, University of Minnesota, College of Pharmacy, November 1993, Minneapolis, Minnesota

DIDACTIC TEACHING

PharmD, Bachelors of Science, and Clinical Pharmacy Translational Sciences Curriculums (University of Michigan College of Pharmacy)

Fall Semester

2016-2019	Pharmacy 702-Pharmacology and Therapeutics III Role: Lecturer (4.5 contact hours)
2010-2012	Pharmacy 451-Pharmaceutical Care III Role: Case Evaluator (4 contact hours)
2009-2016	Pharmacy 431-Pharmacology and Therapeutics II Role: Lecturer (4.5 contact hours)
2007-2009	Pharmacy 680-PharmD Seminar Role: Coordinator (24 contact hours)
2006-2019	Pharmacy 680-Pharm D Seminar

Role: Preceptor (2 students/year)

Winter Semester

2019-present	Pharmacy 727-Career Development for PhD Students and Post-Doctoral Fellows Role: Co-Coordinator (15 contact hours)
2019-present	Pharmacy 216-Introduction to Precision Health Role: Coordinator (15 contact hours)
2018-present	Pharmacy 647-Introduction to Clinical Trials Role: Coordinator (30 contact hours)
2011-2016	Pharmacy 432-Pharmacology and Therapeutics II Role: Coordinator (60 contact hours)
2010-2016	Pharmaceutics 465-Pharmacogenomics Role: Presentation Evaluator (2-4 contact hours)
2010	Pharmacy 402-Introduction to the Profession Role: Group Facilitator (3 contact hours)
2010-2020	Pharmacy 452-Pharmaceutical Care IV Role: Lecturer (20 contact hours)
2009-2020	Pharmacy 432-Pharmacology and Therapeutics II Role: Lecturer (12 contact hours)
2007-2009	Pharmacy 680-PharmD Seminar Role: Coordinator (30 contact hours)
2006-present	Pharmacy 680-Pharm D Seminar Role: Preceptor (2 students/year)

On Job On Campus (OJOC) Program Curriculum (University of Michigan School of Public Health)

2009-2015	Biostatistics 558/Pharmacy 602 Clinical Trials and Drug Design Role: Coordinator and Lecturer (54 contact hours)
2011-2015	Biostatistics 559 Grant Writing Role: Coordinator and Lecturer (54 contact hours)

Miscellaneous Lectures (University of Michigan School of Medicine, Genetics, and Dentistry)

Fall Semester

2008-2015	Sedative and Hypnotic Pharmacology and Therapeutics Review Presented to the Sleep Medicine Senior Fellows (2 contact hours)
-----------	--

Winter Semester

2009-present	Dental 602 The Neural Basis of Orofacial Pain and Function
--------------	--

- Intro to Pharmacogenetics (2 contact hours)
- 2008-present Pharmacogenetics in Psychiatry
 - Presented to the PGY4 Neuropsychiatry Resident (3 contact hours)
- 2008-2014 Pharmacogenetics for Genetic Counseling
 - Presented to the first year genetic counseling student class (2 contact hours)

PharmD Curriculum (University of Iowa College of Pharmacy)

- 1995-2006 Clinical Psychopharmacology Seminar for to resident physicians in psychiatry, neuropsychology fellows, and advanced practice psychiatry nurses.

Course Coordinator

- 1998–2000 Pharmacotherapy: Psychiatric and Neurologic Disorders (46:153)-3 semester hours
- 2003–2005 Pharmacotherapy: Psychiatric and Neurologic Disorders (46:164)-2 semester hours
- 2005–2006 Introduction to Clinical Pharmacogenetics (46:169) – 2 semester hours
- 2005–2006 Advanced Psychopharmacology (46:204) – 2 semester hours
- 2005–2006 Advanced Psychopharmacology (46:203) – 2 semester hours
- 2006–2006 Pharmacogenetics (46:269) – 3 semester hours
- 2006–2006 Clinical Pharmaceutical Sciences Seminar (46:280) – 2 semester hours

Lecturer

- 2005-2006 Introduction to Clinical Pharmacogenetics (46:169)
- 2002–2006 Advanced Psychopharmacology (46:203 and 46:204)
- 2000–2006 Pharmacotherapy of Psychiatric and Neurologic Disorders (46:164)
- 2003–2006 Clinical Pharmacokinetics
- 1998–2004 Pharmacotherapy: Psychiatric and Neurologic Disorders (46:153)

Previous Teaching August 1996-May 1998

- Drug Induced Diseases (46:173): Drug Induced Liver Disease
- Drug Induced Diseases (46:173): Neuroleptic Malignant Syndrome
- Drug Induced Diseases (46:173): Drug Induced Seizures
- Pharmacotherapy III (46:165): Pharmacotherapy of Insomnia
- Pharmacotherapy III (46:165): Pharmacotherapy of Eating Disorders

Group Discussion Leader:

January 2000-April 2000 Clinical Professional Skills (46:195)

January 1999-April 1999 Clinical Professional Skills (46:195)

January 1998-April 1999 Clinical Professional Skills (46:195)

November 1999: Introduction to Pharmaceutical Care (46:049): Problem Based Learning

November 1998: Introduction to Pharmaceutical Care (46:049): Problem Based Learning

December 1996: Introduction to Pharmaceutical Care (46:049): Constipation

October 1996: Introduction to Pharmaceutical Care (46:049): Allergic Rhinitis

October 1995: Introduction to Pharmaceutical Care (46:049): Asthma

University of Iowa-College of Medicine, Department of Psychiatry

1995-1996 Clinical Psychiatry (73:5). Lecture on Pharmacotherapy and Pharmacology of Antimanic medications given to third year medical students as part of their psychiatry rotation

Pharm D Student Service (University of Michigan)

2009-2012 Faculty Advisor for Academy of Students of Pharmacy Antibiotic Resistance/Hand Washing Committee

2008-2010 Faculty Advisor for Academy of Students of Pharmacy Smoking Education Committee

EXPERIENTIAL TEACHING

Pharm D Curriculum (University of Michigan College of Pharmacy)

Pharm D Investigation Students (Pharmacy 565 and Pharmacy 570 (3 credits annually))

2019-2021

Alyssa George, Angelina Jeong, Briana Kowal

2017-2019

Pooja Kumar

2016-2018

Jessica Gerdes

2015- 2017

Chelsea Liebowitz, Lisa Chen

2014- 2016

David Dadinmov, Jenny Lin

2013- 2015

Charles Yoo, Sonja Grinfeld

2012- 2014

Lydia Beneitz, Erin Dukarski, Sahar Seydin, Josh Johnson

2011-2013

Kristen Gardner, Thomas Vassas, Arnold Andreason,

2010-present

Corey Edge, Nancy Janiczek-Dolphin, Stephen Lott, Anna Polk

2009-2011

Giovanni Lares, Jessica Lynn Moreno, Mirae Shin

2008-2010

Tiffany Scott Horton

2007-2009

Amber Bradley, Heidi Cole, Carrie Deierlein, Jillian Descourouez, Dustin Gladden, David Johnson, Elizabeth McCarty, Megan Meden, Jennifer Ng, Mira Patel Elizabeth Renner, Janet Sachenko, Jerome Stevens, Zhenyi Zhang

Research Clerkship

2007-present Pharmacy 690 Elective Clerkship Preceptor (2-6 students per year)

PharmD Curriculum (University of Iowa College of Pharmacy)

Research and Clinical Clerkship

2001 – 2006	Pharmacogenetics Research Clerkship (46:184) 4 semester hours
1997 –2001	Psychiatry Pharm.D. Clerkship (46:184) 4 semester hours
1997-2006	Advanced Psychiatry Pharm.D. Clerkship (46:184) 4 semester hours
1996-1999	Psychiatry B.S. Clerkship (46: 184) 4 semester hours
1997	Pharmacy project elective (46:101) 3 semester hours

Summer Multidisciplinary Clinical Researchers in Training Program (MCRiT) Students (Michigan Institute for Clinical Research (MICHHR))

June-August	2007	Duong Nguyen
June-August	2008	Megan Meden
June-August	2008	Jim Stevenson
June-August	2009	Stephen Lott
June-August	2010	Kristen N. Gardner
June-August	2011	Arnold Andreasen
June-August	2011	John Zaccardelli and Charles Yoo
June-August	2017	Steven Gabriel

Summer Multidisciplinary Clinical Researchers in Training Program (MCRiT) Global Students (Michigan Institute for Clinical Research (MICHHR))

June-August	2013	Alena Wu
June-August	2014	Emily Van Wieren, Craig Michael, Charlotte Buckley
June-August	2015	Blaise Nudeke, Brian Pauls, Blake Jackson
June-August	2016	Erika Kim

POST-GRADUATE EDUCATION

Residency Research Lecture Series (University of Michigan)

2009-2013 Outcome Variables, Reliability/Validity/Confounding
2009-2013 Data Collection Instruments

Residency Preceptor (University of Iowa)

1998-1999 Brian Lund, Pharm.D.
Pharmacy Psychiatry Residency Program
University of Iowa, College of Pharmacy

Psychopharmacology Fellowship Preceptor (University of Michigan)

2017-2019 Beatriz Mitrzyk, Pharm.D,
Psychopharmacology and Pharmacogenetics Fellowship
University of Michigan, College of Pharmacy
2014-2017 Kristen Weise, Pharm.D,
Psychopharmacology and Pharmacogenetics Fellowship
University of Michigan, College of Pharmacy
2014-2017 Stephanie Flowers, Pharm.D, Ph.D.
Psychopharmacology and Pharmacogenetics Fellowship
University of Michigan, College of Pharmacy
2011-2014 Kyle Burghardt, Pharm.D.
Psychopharmacology and Pharmacogenetics Fellowship
University of Michigan, College of Pharmacy

Psychopharmacology Fellowship Preceptor (University of Iowa)

2002–2005 Jeffrey R. Bishop, Pharm.D. M.S.
Psychopharmacology and Pharmacogenetics Fellowship
University of Iowa, College of Pharmacy
2001-2004 Tami Argo, Pharm.D., M.S.
Psychopharmacology Fellowship
University of Iowa, College of Pharmacy
2000-2002 Ryan Carnahan, Pharm.D., M.S.
Psychopharmacology Fellowship
University of Iowa, College of Pharmacy
1999-2001 Brian Lund, Pharm.D., M.S.
Psychopharmacology Fellowship
University of Iowa, College of Pharmacy
1996-1999 Kristy Bever Stille, Pharm.D.
Psychopharmacology Fellowship

Graduate Students Advisor (University of Michigan)

2020-present	Ozioma Edokobi, PharmD/PhD Candidate in Clinical Pharmacy Translational Sciences, University of Michigan Rackham Graduate College
2016-2021	A.Zarina Kraal, MS, PhD Candidate in Psychology, University of Michigan Rackham Graduate College
2014-2016	Jamie Carnahan, PhD Candidate in Pharmaceutical Sciences, University of Michigan Rackham Graduate College (committee member)
2012-2016	Tyler B. Grove, BS, PhD Candidate in Psychology, University of Michigan Rackham Graduate College
2008–2009	Kelan Thomas, Pharm.D., Master Candidate in Clinical Research, Multidisciplinary Clinical Researchers in Training Program (MCRIT), University of Michigan College of Pharmacy and Michigan Institute for Clinical and Health Research
2006-2009	Jessica Moline, B.S., Master Candidate in Genetic Counseling University of Michigan, Human Genetics, Genetic Counseling Program

Masters Students Advisor (University of Iowa)

2005–2006	Jesse Hollanbaugh, Pharm.D., Ph.D. Candidate in Clinical Pharmaceutical Sciences, University of Iowa College of Pharmacy, Clinical and Administrative Division
2004–2006	Mohammad Shawaqfeh, Masters Candidate in Clinical Pharmaceutical Sciences, University of Iowa College of Pharmacy, Clinical and Administrative Division
2003–2005	Ying-Chi (Alice) Lin, Masters Candidate in Clinical Pharmaceutical Sciences, University of Iowa College of Pharmacy, Clinical and Administrative Division

Masters Thesis Defense Committees (University of Iowa)

- April 2004: Yen-Ying Lee
- April 2005: Ying-Chi (Alice) Lin
- April 2005: Charlie Lin
- April 2005: Wendy Leu
- April 2006: Mohammad Shawaqfeh

PhD Defense Committees (University of Toronto, Canada)

- December 2014 Nabillah Choudhry

MENTORING

Mentor for Workshops and Mentoring Programs

2020-present	Addressing Equity and Inclusion in Mentoring - Mentor Training (held two to three times yearly)
2017 -present	MICHR Mentoring Academy (held one to two times yearly)
2015	National Research Mentor Network (NRMN) Certification and Training
2011	Michigan Institute for Clinical Research (MICHR) Panel Discussant for “Establishing Value in Research Mentoring: Recognition and Education Workshop” July 21, 2011
2010–Present	Mentor for American College of Clinical Pharmacy Focused Investigator Training (FIT) and Mentored Investigator Research Training (MeRIT) Programs
	2021 mentees
	David Dadimov, PharmD, University of California San Francisco
	Lee Hu Nguyen, PharmD, University of California Irvine
	Titola Mitsuko Afolabi, PharmD, Midwestern University
	Paul Jisuen Won, University of Southern California
	2019 mentee
	Mikel Jones, PharmD – University of Kentucky
	2017-mentee
	Ryan Funk, PharmD, PhD- University of Missouri
	Jennie Jarrett, PharmD, Ed- University of Illinois Chicago
	2016 mentees
	Jason Karnes, PharmD, PhD – University of Arizona
	Ginah Nightingale, PharmD – University of Philadelphia
	Charlene Williams, PharmD– University of North Carolina
	2015 mentees
	Christine Eisenhower, PharmD– University of Rhode Island
	2014 mentees
	Raymond Cha, Pharm.D, - Wayne State University
	Allison Blackmer, PharmD – University of Michigan
	Emi Minejima, PharmD – University of Southern California
	2013 mentees

Hassan Almoazen, Ph.D., University of Tennessee
Jeffrey Gonzales, Pharm.D., BCPS, FCCM – University of Maryland

Kalen Manasco, PharmD - Georgia Regents University

Catherine O'Brien, PharmD - University of Arkansas

2011 mentees

Neha Sheth, Pharm.D., University of Maryland

Rustin Crutchley, Pharm.D., University of Houston

2010 mentees

Roy Parish, B.S. Pharm.D., University of Louisiana

Pam Pawloski, B.S, Pharm.D., Health Partners Research Foundation

1998-2006 Mentor in the Mentoring program sponsored by Iowa Pharmacy Association

Career Development Award (K award) mentoring/collaboration

Paul Burghardt, Ph.D. Assistant Professor, University of Michigan, School of Medicine, Department of Psychiatry

Simon Evans, Ph.D. Assistant Professor, University of Michigan, School of Medicine, Department of Psychiatry

Michael Dorsch, Pharm.D. Clinical Assistant Professor, University of Michigan, College of Pharmacy, K23 Mentor

Cathy Van Poznek M.D. Assistant Professor, University of Michigan, School of Medicine, Department of Oncology, K23 mentor

Jess Fiedorowitz, M.D. Assistant Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Mentor

Chadi Calarge, M.D. Assistant Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Mentor

Kelly Lee, Pharm.D. Assistant Professor, University of California San Diego, College of Pharmacy, K23 Mentor

Fu Luan, M.D. Assistant Professor, University of Michigan, School of Medicine, Department of Nephrology, K23 Mentor and mentor on other grants

Shannon Saldana, Pharm.D., Assistant Professor, University of Cincinnati Children's Hospital, K23 Mentor

Leigh Beglinger, Ph.D. Associate Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Consultant

David Moser, Ph.D., Associate Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Consultant

Additional Mentees (University of Michigan College of Pharmacy)

Michael Dorsch, Pharm.D., Assistant Professor
Jamie Park, Pharm.D. Clinical Professor
Rima Mohammad, PharmD, Clinical Assistant Professor
Daniel Hertz, PharmD, PhD, Assistant Professor
Toni Coe, PharmD, PhD, Assistant Research Professor
Jasmine Luzum, PharmD, PhD, Assistant Professor
Corey Lester, PharmD, PhD, Assistant Research Professor

Additional Mentees (Touro University College of Pharmacy)

Tristan Lindfelt, Pharm.D. BCPS, Assistant Professor of Clinical Sciences & Residency Director

PROFESSIONAL AFFILIATIONS:

2021-present	American Society for Clinical Pharmacology and Therapeutics (ASCPT)
2020-present	Pharmacogenomics Research Network, Founding member
2019-present	University of Michigan Precision Health
2014-present	Society of Biological Psychiatry, Member
2012-present	American College of Neuropsychopharmacology (ACNP) Full Member
2007-present	Schizophrenia International Research Society (SIRS)
2006-present	University of Michigan Depression Center
2005–present	Schizophrenia Research Forum
1999-2006	American Association of Geriatric Psychiatry (AAGP)
1998-present	National Alliance for the Mentally Ill (NAMI)
1998-present	College of Psychiatric and Neurologic Pharmacists (CPNP) Founding Member
1997-present	American Association of Colleges of Pharmacy (AACP)
1996-present	The International Society for the Study of Xenobiotics (ISSX)
1996-present	International Society of Psychiatric Genetics (ISPG)
1994-present	American College of Clinical Pharmacy (ACCP)
	1998–present Full Member

	1994–1998	Associate Member
1998-2006		Iowa Pharmacy Association (IPA)
1994-1998		Iowa Pharmaceutical Association (IPA)
1994-2004		Johnson County Pharmacists' Association (JCPA)
1992-1994		American Pharmaceutical Association (APhA)
1992-2004		American Society of Health-Systems Pharmacists (ASHP) Psychopharmacy/Neurology Network member
1992-1993		Minnesota Pharmaceutical Association (MPhA)
1989-1992		Academy of Student of Pharmacy (ASP)
1992-2006		Kappa Psi Pharmaceutical Fraternity, Graduate Chapter.
1989-1992		Kappa Psi Pharmaceutical Fraternity, Collegiate Chapter.

COMMITTEE AND ADVISER APPOINTMENTS

University of Michigan, College of Pharmacy

2019-present	Chair, Graduate Education Committee
2019	Chair, Clinical Social and Administrative Sciences Department Promotion Review Committee
2014	Chair, Clinical Social and Administrative Sciences Department Promotion Review Committee
2013-2014	Chair, Dean Search Committee
2013-2016	International Committee
2011	Faculty Search Committee, Clinical Educator Position
2010-present	Research Resources Committee
2010-2013	Accreditation Steering Committee
2010-2013	College of Pharmacy Executive Council
2010-2019	Self Care and Therapeutic Curriculum Sub Committee
2009-2012	Faculty Development and Assessment Committee
	2010-present Co-Chair
2009-2017	Pharmacogenetics Curricular Sub-committee
2008-2013	Clinical Social and Administrative Sciences Research Seminar Chair
2008	Faculty Search committee, Psychopharmacology Clinical Pharmacist
2007-2010	Pharm.D. Investigations Committee
2007-2010	Valteich Review Committee
2007	Faculty Search committee, Psychopharmacology Clinical Pharmacist

University of Iowa, College of Pharmacy

2004–2005	Committee for Review of Dean
2004–2005	Clinical and Administrative Division Faculty Search Committee
2003–2004	Clinical Scientists PhD Task Force
2002–2006	Space and Laboratory Utilization Committee
2002–2003	Pharmaceutical Sciences Division Head Search Committee
2002	CAP Faculty retreat planning committee
2000 – 2006	University of Iowa Student Pharmacy Recovery Network Committee
1999-2000	Clinical and Administrative Division Academic Affairs Committee
1999-2000	Committee for the Development of a Bachelors of Science in Pharmaceutical Chemistry
1997-2006	Faculty Adviser, Kappa Psi Pharmaceutical Fraternity, In
1998- 2000	Curriculum Committee Subcommittee For The Coordination of Therapeutics, Medical Chemistry, And Pharmacology
1998-2000	Ambulatory Pharmaceutical Care Quality Improvement Team, University of Iowa Hospital and Clinics Department of Pharmaceutical Care
1998-1999	Women’s Health Initiative Planning Committee
1998-1998	Committee for Review of Dean

University of Michigan

2021-present	Member, Student Mental Health Committee- Graduate/Professional Student Needs Work Team
2021-present	Member, University of Michigan Joint Institute Grant Review Committee
2021-present	Member, Provost’s Committee for Visitor Policies
2021-present	Member, UMOR’s Committee for Data Analysis Needs Assessment
2020-present	Member, Laboratory Research Safety Committee
2019-2020	Member, Michigan Institute for Clinical and Health (MICHR) Director Search
2019-2020	Member, Depression Center Chair Search Committee
2018-present	Member, Depression Center LINC Committee
2016-2018	Member, President Schlissel’s Precision Medicine Task Force
2016-present	Promotion and Tenure Reviewer, Provost Office
2014-2015	Member, Pharmacology Department Chair Search Committee
2014-2016	Center for Research on Learning and Teaching (CRLT) Advisory Board
2014-2015	Michigan Institute for Clinical Research (MICHR), Education & Mentoring Group Leadership Team Member, Mentoring lead
2013-present	Michigan Institute for Clinical Research (MICHR), Education & Mentoring Group Leadership Team Member

- 2009-2013 Member Scientific Review/Research Committee, Michigan Institute for Clinical Research (MICHR) – funded through the CTSA program (NCRR UL1RR024986)
- 2008-present University of Michigan Depression Center Steering Committee Member

University of Iowa

- 2005–2007 Office for the Vice President of Research, Scientific Misconduct Committee
- 1998-2000 Coalition for Long Term Mental Health Care, University of Iowa, College of Nursing

State and County Committees (Michigan)

- 2006-2012 Washtenaw Community Health Organization Outcomes and Evaluation Committee, Washtenaw County Michigan

State and County Committees (Iowa)

- 2004–2006 Health Iowans 2020-Mental Health Chapter Team Member, Department of Public Health, State of Iowa
- 2002-2003 Nominations Committee, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa
- 2002–2003 Programming Committee, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa
- 2001-2002 Past President, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa
- 2000-2001 President, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa
- 1999-2000 President Elect, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa
- 1998–2006 Iowa Pharmacy Recovery Network (IPRN), Iowa Pharmacy Association
- 1998-2003 Health Iowans 2010-Mental Health Chapter Team Member, Department of Public Health, State of Iowa
- 1998-2000 Communications Committee, Iowa Pharmacy Association

National Committees and Appointments

- 2021-present Workforce Development Taskforce, National Center for the Advancement of Translational Science (NCATS)
- 2019-present Education and Training Committee, American College of Neuropsychopharmacology (ACNP)
- 2018-present Pharmacotherapy Publications Board of Trustees, American College of Clinical Pharmacy (ACCP)

2017-present	Association for Clinical and Translational Science Career Development Committee
2017-2019	Chair, Precision Medicine Taskforce, American College of Clinical Pharmacy (ACCP)
2016-present	Association for Clinical and Translational Science (ACTS) Board of Directors
2014	Chair, Member Relations Committee, American College of Clinical Pharmacy (ACCP) Research Institute
2012-2013	President, American College of Clinical Pharmacy (ACCP) Research Institute Board of Trustees
2010	Savvy Psychopharmacology Department Editor, <i>Current Psychiatry</i>
2010-2011	Annual Meeting and Spring Forum, Poster Chair, American College of Clinical Pharmacy (ACCP)
2010-2014	American College of Clinical Pharmacy (ACCP) Research Institute Board of Trustees
2009-2010	Pharm.D. Post Graduate Education Summit Planning Committee
2008-2011	Annual Meeting Poster and Awards Chair/Co-Chair, College of Psychiatric and Neurologic Pharmacists (CPNP)
2008-2010	Secretary, Board of Directors, College of Psychiatric and Neurologic Pharmacists (CPNP)
2007-2020	Member, National Alliance for Mentally Ill (NAMI) Scientific Research Council
2006	Pharm.D. Pathways to Biomedical Research, NIH conference Attendee
2006-2007	American Association of College of Pharmacy (AACP) Clinical Scientist Task Force
2007-2009	American College of Clinical Pharmacy (ACCP) Research Institute Mentored Investigator Development Program Committee
2007-2008	American College of Clinical Pharmacy (ACCP) Research Institute Researcher Development Committee
2006-2009	American College of Clinical Pharmacy (ACCP) Research Institute Research Training Committee
2006-2009	Chair, Research Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)
2004-2006	Chair, American College of Clinical Pharmacy CNS Practice and Research Network group
2004-2010	Research Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)
2002-2005	Fellowship Review Committee, American College of Clinical Pharmacy
2001-2004	Chair, Awards and Nominations Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2000-2001	Co-Chair, Awards and Nominations Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)
1999–2002	Psychiatry Board Certification Preparatory Course Development Committee, American College of Clinical Pharmacy
1998-2004	Awards and Nominations Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)
1997-1998	Chair, Research/Clinical Practice/Networking Committee ACCP, CNS Practice and Research Network group

Patient-Centered Outcomes Research Institute (PCORI)

August 2012	Patient-Centered Outcomes Research Institute (PCORI) Grant reviewer
-------------	---

National Institutes of Health Reviews

2020	Substance Abuse and Mental Health Services Administration (SAMHSA) Grant Reviewer
2016	NIH Precision Medicine Special Emphasis Panel ZRG1 IMST-R (50) R
2015	NIH Precision Medicine Special Emphasis Panel ZRG1 IMST-R (50) R
2012	Patient Center Outcomes Research Institute (PCORI) Reviewer
September 2012	NCATS Therapeutics Discovery Reviewer
July 2012	NIMH Program Grant Reviewer, ZRG1 PSE-B (03) M
July 2012	NIDDK Program Grant Reviewer, Special Emphasis Panel ZRG1 EMNR-Q (50) R-PAR-08-160: Metabolic Effects of Psychotropic Medications
January 2012	NIGMS Program Grant Reviewer, 2012 NIH Director's Pioneer Award Program
December 2011	EMNR Program Grant Reviewer, OD-11-003: Specialized Centers of Research (SCOR) on Sex Differences (P50).
January 2011	NIGMS Program Grant Reviewer. 2012 NIH Director's Pioneer Award Program
July 2010	NIDDK Program Grant Reviewer, Special Emphasis Panel ZRG1 EMNR-Q (50) R-PAR-08-160: Metabolic Effects of Psychotropic Medications
January 2010	NIGMS Program Grant Reviewer, Special Emphasis Panel ZGM1 PPBC-5 (KB)
December 2009	NIGMS Program Grant Reviewer, Special Emphasis Panel ZRG1 GGGM (52)R
July 2009	NIA Program Grant Reviewer, Special Emphasis Panel ZAG1 ZIJ-3 04

June 2007	NIA Program Grant Reviewer, Special Emphasis Panel ZAG1 ZIJ-8 03
October 2006	NIMH Program Grant Reviewer, Special Emphasis Panel ZMH1-ERB-L-02
July 2006	NIA Program Grant Reviewer, Special Emphasis Panel ZAG1 ZIJ-8 03
October 2005	Committee Chair, NIMH Special Emphasis Panel ZMH1-ERB-L-02

Additional Grant Reviews:

2013	Portugal Grant Reviews
2011	ZonMw's 'Klinische Fellows' programme, The Netherlands
2010-present	Italian Ministry of Health
2006-2008	American College of Clinical Pharmacy Research Institute
2004	Ontario Mental Health Foundation
2003-2006	University of Iowa General Clinical Research Center
2003-2006	University of Iowa Biosciences Initiative Grant Program

Other Professional Activities:

Reviewer:

ASHP Supplemental Standard and Learning Objectives for Residency Training in Psychiatric Pharmacy Practice, 1997

ASHP Supplemental Standard and Learning Objectives for Residency Training in Clinical Pharmacokinetics Practice, 1997

Clinical Positions:

1994-2006	Clinical Pharmacist on Medical Psychiatry Unit (4SE), University of Iowa Hospital and Clinics, Iowa City, IA,
1994-2006	Clinical Pharmacist for Clinical Liaison Psychiatry Team, University of Iowa Hospital and Clinics, Department of Psychiatry, Iowa City, IA
1996-2006	Consultant Pharmacist for IMPACT program, University of Iowa Hospital and Clinics, Department of Psychiatry, Iowa City, IA.

Moderator:

Incorporating Health Services Research into Practice – Parts I and II. College of Psychiatric and Neurologic Pharmacists Annual Meeting, Phoenix, Arizona, May 2011

The Great Eight, American College of Clinical Pharmacy Annual Meeting, Austin, Texas, October 2010.

Central Nervous System Focus Session, American College of Clinical Pharmacy Annual Meeting, St. Louis, Missouri, October 2006.

Psychiatry Platform Presentation Session, American College of Clinical Pharmacy Annual Meeting, Kansas City, Missouri, October 1999.

Awards and Honors:

- | | |
|---------------|---|
| April 2019 | Roland T. Lakey Award, Wayne State University (postponed due to COVID19) |
| April 2012 | Michigan Institute for Clinical and Health Research (MICHHR) Distinguished Mentor Award in Clinical and Translational Research |
| August 2007 | Fellow, American College of Clinical Pharmacy |
| June 2007 | Guest Editor, <i>Journal of Pharmacy Practice</i> |
| August 2006 | Editorial Board Member, <i>Pharmacotherapy</i> |
| April 2003 | Young Investigator of the Year Award, American College of Clinical Pharmacy |
| October 2002 | Honorable Mention for Best Poster Award, American College of Clinical Pharmacy Annual Meeting |
| April 2002 | Participant in the Future Leaders in Psychiatry Meeting sponsored by the Emory University and Janssen Pharmaceuticals |
| June 2000 | Participant in the New Technology in the Learning Environment (nTITLE) Summer Faculty Workshop sponsored by the Center for Teaching, University of Iowa Libraries, and Information Technology Services at the University of Iowa. |
| July 1999 | Participant in the Summer Research Institute sponsored by the National Institute of Mental Health (NIMH) and American Association of Geriatric Psychiatry (AAGP) |
| August 1998 | Participant in Leadership Pharmacy Conference sponsored by Iowa Pharmacy Association and Pharmacy Society of Wisconsin |
| November 1997 | Best Poster Award, American College of Clinical Pharmacy Annual Meeting |
| July 1995 | American College of Clinical Pharmacy Psychopharmacology Fellowship |
| June 1992 | Hallie Bruce Memorial Award, for outstanding achievement in hospital pharmacy |
| 1991-1992 | Kappa Psi Scholarship Honors |
| 1991 | Skoglund Memorial Scholarship, Fairview Riverside Medical Center. |
| 1988 | Co-founder of the Women's Awareness House at Augsburg College. |
| 1988-1989 | Secretary of Orientation Program, Augsburg College. |
| 1987-1989 | Orientation Leader, Augsburg College |
| 1988-Present | Omicron Delta Kappa National Honor Society, Augsburg College |

1987

Holman Memorial Chemistry Scholarship, Augsburg College